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1 Introduction 
Radiotherapy is an essential component of the management of prostate and breast cancer. Most 
patients become long survivors; however, irradiation may increase the risk of non-cancer-
related morbidities. 
Pelvic irradiation including the prostate, seminal vesicles, and lymphatic regions is an integral 
component of high-risk [1], organ-confined, and locally advanced prostate cancer management. 
The tolerance of normal tissues limits dose escalation and tumour control probability and 
increases the incidence of gastrointestinal morbidity. One of the most important factors related 
to the probability of the complications is the total dose of radiotherapy (RT) delivered to the 
pelvic organs. The irradiated rectal and bowel volume may be reduced by using intensity 
modulated (IM) and image-guided RT (IGRT) and optimal patient positioning. 
Radiation-induced heart damage clearly depends on the dose exposed to its different structures 
[2,3]. With the aim of cardiac dose sparing and avoidance, numerous new methods have been 
developed [3,4]. These include, among others, partial breast irradiation (PBI) (reducing the 
volume to be irradiated) and prone positioning (operating by separating the heart and the 
radiation fields). The approaches available for the implementation of PBI include among others 
3-dimensional-conformal radiation therapy (3D-CRT), with multiple static photon, and/or 
electron fields, intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc 
radiotherapy (VMAT). Based on confirmatory results of the efficacy and safety of most 
techniques, eligibility for PBI has been extended to previously medium-risk cases, and 
guidelines recommend the technique more widely than before [5-7]. Prone positioning has 
become an alternative of conventional supine positioning in some centres, providing dramatic 
reduction in the ipsilateral lung dose, and in many cases significantly reducing heart exposure, 
too. 
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2 Aims 
 
2.1 To assess whether the supine or prone position (in the latter with a belly board), and the 
application of the IMRT technique would result in the reduction of the radiation dose to the 
organs at risk (OARs) such as the rectum, colon, and small intestines during pelvic RT of 
prostate cancer patients. 
2.2 Developing a simple clinical method in a prospective study for the operation of an 
already validated model for the prediction of the individually preferable treatment position 
(prone versus supine) during left breast radiotherapy. 
2.3 To implement individualized accelerated partial breast irradiation (APBI) based on 
optimal dose distribution and OAR protection and identify the individually most advantageous 
technique by considering various tumour- and patient-related factors. 
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3 Patients and methods 
 
All the procedures followed were in full accordance with the ethical standards of the responsible 
committees on human experimentation (institutional and national) and with the Helsinki 
declaration. All patients gave informed consent before enrollment into the study authorized by 
the national and regional ethics committees. 
 
3.1 Prone positioning on a belly board decreases rectal and bowel doses in pelvic IMRT for 
prostate cancer 
 
3.1.1 Patient population 
The prospective analysis included patients with a histologically confirmed, high risk [10], 
localized or locally advanced (2009 TNM classification [8] stage T2-4 N0-1 M0) prostate 
cancer graded according to the Gleason score system [9], receiving a definitive pelvic RT at the 
Department of Oncotherapy, University of Szeged, Hungary. The tumour stage assessment was 
based on the findings of thoracic computed tomography (CT), abdominal and pelvic CT and 
magnetic resonance imaging (MRI), and whole-body bone scintigraphy. Clinical and 
pathological data were extracted from the patient files. 
3.1.2 Patient positioning and computed tomography scanning 
Patients were positioned on the supine and prone pelvis modules of the All in One (AIO) 
Solution (ORFIT, Wijnegem, Belgium) system. In supine pose, the patient was positioned with 
bent knees, and the genitalia were distracted with extruded polystyrene blocks. In prone 
position, a belly board was applied to allow the abdomen to extend into its aperture, and a 
polystyrene wedge was placed between the buttocks. For immobilization a six-point 
thermoplastic mask fixation (Pelvicast system, ORFIT, Wijnegem, Belgium) was employed. 
All patients underwent five-millimetre slice-increment topometric CT scanning in both 
positions from the diaphragm to the level of 10 cm below the femoral necks, using a Somatom 
Emotion 6 CT Simulator (Siemens, Erlangen, Germany). CT scanning was prepared with full 
bladder according to our internal protocol and following an antiflatulent diet for at least 7 days 
prior and during RT delivery. 
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3.1.3 Target and critical structure delineation 
The gross tumour volume (GTV), clinical target volume (CTV), planning target volume (PTV), 
and OARs were delineated in the ARIA Oncology Information System (Varian Oncology 
Systems, Palo Alto, CA, USA) in both positions by radiation oncologists and reviewed by an 
experienced radiologist. The prostate was contoured as GTVp. The proximal thirds, or in case 
of involvement, the full extension of the seminal vesicles and pathologic lymph nodes (GTVN), 
if present, were delineated considering MRI records. CTVN included the parailiac, upper 
subaortic presacral and obturator lymph nodes, contoured according to the RTOG GU Radiation 
Oncology Specialists Reach Consensus [10]. PTVp included GTVp with a 10 mm margin along 
the supero-inferior, left–right axis, in anterior direction and 7 mm in posterior direction. PTVpvs 
was defined as the combination of GTVp and seminal vesicles with a safety margin of 10 mm 
in posterior direction and 15 mm in any other directions. PTV was determined as PTVpvs, a 
7 mm margin around CTVN and 10 mm around GTVN, if present. The rectum, large and small 
intestines, urinary bladder, femoral heads, and bony structures were outlined as OARs. The 
rectum was defined from the ischial tuberosities to the sigmoid flexure, but at least 2 cm above 
PTVpvs. Each rectal section, the whole rectum (R), the segment at the height of the prostate 
(R1), and R1 + 10 mm along the supero-inferior axis (R2) were individually delineated. Large 
and small bowel volumes contained all identifiable segments. The bladder was delineated from 
the apex to the dome [11]. 
3.1.4 Rectal extension and rectum–prostate distance measurement 
At the height of the largest antero-posterior (AP) diameter of the prostate, rectal diameters along 
the AP and left–right axis were defined, and perpendicular lines were created from the centre 
and lateral edges of the back wall of the prostate to the outer anterior rectal wall in both supine 
and prone positions (Figure 1). Two independent radiation oncologists performed rectum–
prostate distance measurements, both of them twice. 
 
3.1.5 IMRT planning and dosimetric analysis 
IMRT planning was performed using the Eclipse treatment planning system (Varian Oncology 
Systems, Palo Alto, CA, USA). The prescribed doses were 45 Gy to the PTV (1.8 Gy/day, 5 
days/week), 14 Gy boost to the PTVpvs and 18 Gy boost to the PTVp, both delivered in daily 
11 
 
 
2 Gy fractions, 5 days per week, boost irradiations given sequentially. OAR dose constraints 
were determined as the following [10]: V55Gy (bladder) ≤ 50%, V70Gy (bladder) ≤ 30%; 
V50Gy (rectum) ≤50%, V70Gy (rectum) ≤20%; V50Gy (colon) ≤ 50%, V70Gy (colon) ≤ 20%; V52Gy (small 
intestine) = 0%; V50Gy (femoral heads) < 5%. For the coverage of the PTV sliding window IMRT plans 
were designed in both positions with a seven-field beam arrangement using 6 MV photon beam 
quality, consisting coplanar beam directions as the following: in prone position 0°, 136.1°, 
208.3°, 258.7°, 101.7°, 306.1° and 55.2°, in supine position 0°, 38.2°, 98°, 142°, 215.7°, 269.5° 
and 318.2°. For the PTVpvs and PTVp VMAT plans were generated in both positions using 6 
MV photon beam quality, 181°–179° and 179°–181° gantry angles and 30° and 15° collimator 
angles, respectively. IMRT plans were created to obtain a 95% coverage of the PTV with the 
95% isodose curve. The highest priority was PTV coverage, and the second one was the sparing 
of OARs. Planning assistant contours of the PTV, PTVpvs, and PTVp were designed with 
uniform margins of 15 mm, 30 mm, 40 mm, and 50 mm in both positions. Dose-volume 
histograms (DVHs) were calculated for all defined volumes. Data of mean volumes of the 
contoured structures, mean absolute volumes of the small bowel and colon receiving 20–50 Gy, 
mean relative volumes of the rectal segments receiving 30–75 Gy and of the bladder receiving 
30–70 Gy doses and mean of doses regarding PTV D95, PTVpvs D95, and PTVp D95 were 
collected. 
 
3.1.6 Radiation treatment and image-guidance 
Irradiation was carried out by using a Varian TrueBeamSTx (Varian Oncology Systems, Palo 
Alto, CA, USA) in prone position. Image-guidance was based on daily kV-cone beam CT 
(CBCT) scanning of the pelvis prior to treatment, using the standard mode settings: 125 kV, 
80 mA, 13 ms, and half-fan bowtie filter. An automatic match algorithm was used to match the 
bony structures displayed on the planning CT and the CBCT. 
 
3.1.7 Statistical analysis 
Data were reported as mean ± standard deviation (SD), mean ± standard error (SE) or median 
values. The difference between the volumes and doses in supine and prone position was 
analysed with the paired samples t-test. Intraobserver and interobserver variabilities were 
calculated from the mean of distances by using correlation analysis, given a correlation 
12 
 
 
coefficient (r). SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA) was used to perform the 
analysis. A p value < 0.05 was considered significant. 
 
Figure 1. Rectal extension and rectum–prostate distance measurement: At the height of the 
largest antero-posterior diameter of the prostate perpendiculars were created from the centre 
and both lateral edges of the posterior prostate wall to the anterior rectal wall in both prone 
(a) and supine (b) positions. Larger rectal diameters in prone, smaller in supine position in 
case of the same patient at the same time 
3.2 A simple clinical method for predicting the benefit of prone vs. supine positioning in 
reducing heart exposure during left breast radiotherapy 
 
3.2.1 Outline of the study 
First, a single CT slice image at the middle of the heart (reference plane, Pref) was acquired with 
the help of an AP scout view in the supine position (Figure 2A). On that CT scan, the shortest 
distance between the anterior surface of the left anterior descending coronary artery (LAD) and 
the chest wall (Dmed) and the area of the heart (Aheart) included in the radiation fields were 
measured after placing a straight line between the border of the ipsilateral latissimus dorsi 
muscle and the lateral edge of the sternum (Figure 2B); these data (representing the topography 
of the heart) were introduced to the calculator together with the patient’s body mass index 
(BMI) (which correlated with the volumes of the breast and heart) as previously described in 
detail [12]. 
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Figure 2. The simple clinical tool generates patient-specific data to predict the benefit of 
prone positioning. After selecting the reference plane (Pref) at the middle of the heart on the 
AP scout view (A), a single CT slice is acquired for the measurement of those determinants 
(Dmed and Aheart) (B) which operate the calculator to provide estimates of the doses to the LAD 
or heart. 
Conformal radiation treatment plans were generated in both positions using conventional 6 MV 
tangential photon fields set up isocentrically and median 2 (1–3) individually weighted 6/15 
MV segmental fields superimposed on the tangential fields using a multileaf collimator as 
described [12,13]. Wedges were used in almost all supine radiation plans. A mean dose to the 
PTV of 50 Gy (25 fractions) and a uniform distribution (–5% + 7%) of the prescribed dose to 
95% of the PTV, were aimed at. The consistency of all contouring activities had been ensured 
by a chief radiation oncologist and an experienced radiologist [14]. Equivalent heart and LAD 
volume contouring in either setup was ensured by one author. In the next ‘‘routine clinical 
practice” set of 60 patients, the acquisition of a single series of CT images according to the 
suggestion of the calculator was aimed at, and a second CT series was taken only if any of the 
dose constraints approved for the specific position were not reached in the position suggested 
by the calculator. In this series of patients’ dose constraints were specified on the basis of 
previously recorded data. The upper range limits of the 90% percentile of dosimetry data in the 
preferred position were the following: mean LAD dose [MDLAD]: 12.9 Gy and 12.5 Gy, 
V25Gyheart: 2.4% and 4.7%, in the prone position and supine position, respectively. In true 
discordant cases, our strategy for selecting treatment position was to consider the LAD dose as 
a primary decisive factor. 
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In the validation set, data on LAD and heart dose differences between the two treatment 
positions were extracted from the planning system and estimated by the calculator, whereas in 
the ‘‘routine clinical practice” series only the estimated dose differences were available. 
Analyses were performed on 1. the equivalence of the Pref with the median plane of the full 
series of CT scans acquired in the supine position (Pmed) and 2. the effect of plane miss on the 
patient-related determinants and choice of preferable position. The sensitivity and specificity 
of this simple clinical method were evaluated based on the dosimetry data obtained using the 
topogram for selecting the position (n = 100). In the ‘‘routine clinical practice” series, the 
acceptability of the position as predicted by the calculator, the LAD and heart doses achieved 
without taking 2 CT series, and the need of performing a second CT series and changing 
position or irradiation technique were analysed. 
 
3.2.2 External testing 
The supine and prone CT series and supine topogram of patients included in the study 
‘‘Individualized positioning for maximum heart and index breast protection during breast 
irradiation: comparative study between Prone and Supine (Approval: 26/09/2013, 
B707201318246) were retrospectively used for independent testing. The protocol of patient 
positioning, delineation and radiation treatment planning has been described [15]. 
 
First, Pref was selected on the topogram. Then, the predictors BMI, Dmed, Aheart as measured in 
Pref were introduced to the calculator. As a second step, Dmed, Aheart were also measured in Pmed. 
LAD and heart dose differences between the two treatment positions extracted from the 
planning system and estimated by the calculator were analysed. Finally, the correctness of Pref 
was evaluated. 
 
3.2.3 Statistical methods 
The calculator had been developed based on linear regression models utilizing the patients’ 
anatomical features, with ΔMDLAD and ΔV25Gyheart as dependent variables [12]. With a single 
cut-off point, a case was classified to prone positioning when the predicted value exceeded that 
value. 
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Thresholds were optimized based on sensitivity and specificity as calculated from previous [12] 
and present data (Table 1). 
 
 Original method 
(double CT method, 
n=83) 
Simple tool 
(single CT method, 
n=100) 
 Cut-off 
point 
Sensitivity 
(%) 
Specificity 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
 
 
ΔMDLAD (Gy) 
-0.6 66.6 91.1 72.4 91.5 
-0.3 70.8 90.7 75.9 91.5 
0 74.4 90.0 75.9 91.5 
0.3 77.7 88.9 79.3 88.7 
0.6 80.7 87.5 82.8 87.3 
0.9 83.4 86.0 82.8 83.1 
1.2 85.4 83.6 86.2 81.7 
1.5 86.5 81.7 86.2 77.5 
1.8 86.8 79.9 93.1 76.1 
 
 
ΔV25Gyheart 
(%) 
0 47.9 89.7 50 90.8 
0.25 56.2 88.8 58.3 89.5 
0.50 63.2 85.9 64 88 
0.75 72.4 82.4 68 85.3 
1 78.8 77.7 80 85.3 
1.25 84.0 74.0 84 81.3 
1.50 87.4 77.0 92 78.6 
1.75 89.9 62.1 96 74.6 
Table 1 Classification measures for ΔMDLAD and ΔV25Gyheart using a single discrimination 
threshold. Great consistency is seen between the original cohort [12] and the present 
series. 
Sensitivity and specificity were calculated with supine positioning as positive determinant in 
the model. For ΔMDLAD a threshold of 0.6 Gy, and for ΔV25Gyheart a cut-off point of 1.0% were 
chosen. In the definition of the cut-off points, a sensitivity of 80% at the minimum and the 
maximum achievable value of specificity was required. 
 
LAD and heart dose constraints achievable by selecting the preferable position were specified 
by percentage estimation. Statistical analysis was performed with SPSS 22.0 for Windows. 
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3.3 Dosimetric comparison of 3D-CRT, sliding window IMRT and VMAT techniques for 
external beam accelerated partial breast radiotherapy 
 
3.3.1 Patient population 
This prospective clinical cohort trial included women after breast conserving surgery, with an 
age of at least 50 years, diagnosed with a unifocal and unicentric breast cancer of any invasive 
histological type or low risk ductal carcinoma in situ (DCIS), with any hormone receptor and 
human epidermal growth factor receptor-2 (HER2) status, pT1-2 (≤30 mm) tumour size 
removed with at least 2 mm free margin, pN0 axillary status diagnosed by sentinel lymph node 
biopsy or axillary block dissection, without extensive intraductal component (EIC), 
lymphovascular invasion or distant metastases. Excision cavity localization at surgery with 
titanium clips was an inclusion criterion. Exclusion criteria included relative and absolute 
contraindications of irradiation. All cases were discussed at a multidisciplinary tumour board. 
Adjuvant systemic therapy was indicated according to the institutional guidelines. Various 
clinical data including tumour bed situation (lateral, medial/central, upper, lower) within the 
breast was prospectively collected. 
 
3.3.2 Patient positioning and CT scanning 
The patients were positioned supine on an ‘All in One (AIO) Solution’ (ORFIT, Wijnegem, 
Belgium) breast board with the arms raised over the head. For immobilization, diagonal 
thermoplastic mask fixation (ORFIT, Wijnegem, Belgium) was employed. All patients 
underwent five-millimetre slice-increment planning CT scanning from the sternoclavicular 
joint to the level of 2 cm below the submammary fold, using a Somatom Emotion 6 CT 
Simulator (Siemens, Erlangen, Germany). 
 
3.3.3 Target and critical structure delineation 
The CTV included the excision cavity (marked with surgical clips) with a 1.5 cm margin 
extended in all directions, limited by 0.4 cm from the skin surface and by the outer edge of the 
chest wall. For compensating daily setup errors and breathing motions, a universal PTV-CTV 
margin of 0.5 cm was added. As OARs, the ipsilateral uninvolved breast, the contralateral 
breast, the lungs, the heart and the LAD [12,16] were delineated. 
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3.3.4 Treatment planning 
In all cases, 3D-CRT, sliding window IMRT and VMAT plans were generated in the Eclipse 
v13.6 planning system (Varian Oncology Systems, Palo Alto, CA, USA) for a Varian 
TrueBeamSTx (Varian Oncology Systems, Palo Alto, CA, USA) linear accelerator with HD120 
multileaf collimator. In 3D-CRT technology, two 6 MV photon fields were used, closing at an 
angle of approximately 120° (Figure 3A). The definition of field directions was based upon 
tumour location and in left-sided cases the situation of the heart and LAD in relation to the 
PTV. For homogeneous dose distribution, further sub-segments were employed, if necessary. 
Sliding window IMRT planning was carried out applying 6 MV photon energy with a five-field 
beam arrangement of 300°, 350°, 40°, 90° and 150° in left-sided cases and 60°, 10°, 320°, 270° 
and 210° in right-sided cases (Figure 3B). If the target volume was located in the medial or 
lateral area of the breast, an additional ±10° rotation was used, depending on laterality. The 
field direction range of dual arc VMAT was defined by the first and last field of the IMRT plan 
(Figure 3C). The isocentre was placed into the geometric centre of the PTV. For comparability 
purposes the same optimisation parameters were used during inverse treatment planning 
(IMRT, VMAT). If the shortest distance of the geometric centre of the PTV from the body 
surface (d) was <25 mm, in an additional plan of each technique, an ‘en face’ electron beam of 
4-16 MeV energy was applied (Figure 3D), calculating 2/3 of the whole dose with photon and 
1/3 with electron technique. For these fields Newton’s metal apertures were planned to reduce 
normal tissue exposure. For the PTV, a total dose of 37.5 Gy was prescribed (10 fractions, 3.75 
Gy/fraction, 1 fraction/day, 5 times/week), ≥99% of the PTV receiving 95% of the prescribed 
dose and at least 90% of the PTV receiving 100% of the prescribed dose. Ten per cent at most 
of the PTV was allowed to receive >107% of the prescribed dose. 
 
3.3.5 Treatment plan evaluation 
Conformity and homogeneity indexes of the PTV and dose-volume parameters of the OARs 
were defined in every plan. 
Conformation Number (CN) [17]: 
 
𝐶𝑁 =
𝑃𝑇𝑉𝑟𝑒𝑓
𝑉𝑃𝑇𝑉
×
𝑃𝑇𝑉𝑟𝑒𝑓
𝑉𝑟𝑒𝑓
    (Ideal is 1) 
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Figure 3 Beam arrangement in 3D-CRT (A), IMRT (B), VMAT (C) radiotherapy techniques 
and the combination of photon fields with an ‘en face’ electron beam (D) 
PTVref refers to the volume of target receiving a dose equal to or greater than the reference dose, 
in this case the prescribed dose (37.5 Gy). VPTV stands for the volume of target, and Vref is the 
total volume that covered by the reference isodose. 
 
Homogeneity Index (HI) [18] (D2%, D50%, D98%=dose received by 2%, 50% and 98% of PTV, 
respectively): 
To describe plans with a single numerical data, a Plan Quality Index (PQI) was developed based 
on the study of Leung et al. [19], in which the parameters (H)ealthy tissue conformity index, 
(M)erit and (P)enalty functions were generated as follows: 
The (H)ealthy tissue conformity index [20]: 
The target volume coverage was characterized by the ‘(M)erit function’ parameter [19], to 
verify the performance of hot and cold spots within the PTV. As coverage criteria differ from 
𝐻𝐼 =
𝐷2% − 𝐷98%
𝐷50%
 (Ideal is 0) 
𝐻 =
𝑃𝑇𝑉𝑟𝑒𝑓
𝑉𝑟𝑒𝑓
 (Ideal is 1) 
𝑃𝑄𝐼 = √(1 − 𝐻)2 + (1 − 𝑀)2 + (1 − 𝑃)2 (Ideal is 0) 
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prostate irradiation studied by Leung et al. [19], the following limits were applied to determine 
‘M’. Cold spots were defined by the percentage PTV volume covered with the 100% isodose 
curve (at least 90%), hot spots were defined by the percentage PTV volume receiving at least 
107% of the prescribed dose (at most 10%). 
The relative volume of the ipsilateral healthy breast (ipsilateral breast – PTV) receiving at least 
25, 50, 75 and 100% of the prescribed dose (BreastV25%, 50%, 75% and 100%, respectively), the mean 
dose to the ipsilateral lung (Lungmean) and the relative volume of it receiving ≥40% of the 
prescribed dose (LungV40%), the mean dose to the heart (Heartmean) and the relative volume of 
it receiving at least 50% of the prescribed dose (HeartV50%), the mean dose to the LAD 
(LADmean) and the relative volume of it receiving ≥20% of the prescribed dose (LADV20%) were 
collected. 
 
For studying OAR exposure, the calculation algorithm applied by Leung et al. [19] was 
modified to make it suitable for the characterization of risk organ exposure during breast 
irradiation as follows. To describe the exposure of OARs with a single ‘(P)enalty function’ 
parameter [19], specific dose parameters of four OARs compared to the 99% percentile of the 
respective sample population were averaged for each technique. 
 
In right-sided cases: 
In left-sided cases: 
 
 
If the P value were negative in an extreme case (e.g. the exposure of all OARs was high), that 
would have been defined as 0 for further calculations. 
 
𝑀 =
𝑉100%
90 + (1 −
𝑉107%
10 )
100
90 + 1
(Ideal is 1) 
𝑃 =
(1 −
𝐵𝑟𝑒𝑎𝑠𝑡𝑉25%
70 ) + (1 −
𝐿𝑢𝑛𝑔𝑚𝑒𝑎𝑛
10 ) + (1 −
𝐻𝑒𝑎𝑟𝑡𝑚𝑒𝑎𝑛
5 ) + (1 −
𝐿𝐴𝐷𝑚𝑒𝑎𝑛
5 )
4
(Ideal is 1) 
𝑃 =
(1 −
𝐵𝑟𝑒𝑎𝑠𝑡𝑉25%
70 ) + (1 −
𝐿𝑢𝑛𝑔𝑚𝑒𝑎𝑛
10 ) + (1 −
𝐻𝑒𝑎𝑟𝑡𝑚𝑒𝑎𝑛
10 ) + (1 −
𝐿𝐴𝐷𝑚𝑒𝑎𝑛
10 )
4
(Ideal is 1) 
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To select the most favourable irradiation plan for a given patient, PQI values were compared. 
In order to determine an arbitrary threshold of PQI difference that indicates a difference in about 
half of the cases, we defined the PQI difference (PQID) as relevant if exceeded the value of 
0.05. Each plan that reached this critical PQID level was referred to a respective ‘winner method 
group’, while that which did not was referred to the group of equality. 
 
To study if any of the irradiation techniques would be more favourable in subgroups of patients, 
the effects of the volume of the PTV, its distance from the body surface (d) and the quadrant 
where it was situated were analysed. 
 
3.3.6 Statistical methods 
Continuous variables were expressed as mean ± SD. The means of continuous variables in the 
different ‘winner method groups’ were compared with Welch’s one-way ANOVA. After 
significant ANOVA multiple comparisons were conducted with least significant difference 
(LSD) method. The dependence between two categorical variables was examined with 
Pearson’s Chi-squared tests. The relationship between PQI components and PQI values was 
presented with scatter plot. Pearson correlation coefficients were calculated. 
 
The effect of the addition of an electron beam to photon beams and treatment technique choice 
(3D-CRT vs. IMRT vs. VMAT) was analysed with two-way repeated measures (within 
subjects-within subjects) ANOVA. A p<0.05 was regarded as statistically significant. Statistical 
software IBM SPSS version 24 was used for statistical analysis.  
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4 Results 
 
4.1 Prone positioning on a belly board decreases rectal and bowel doses in pelvic IMRT for 
prostate cancer 
 
4.1.1 Patient population 
Between October 13, 2016 and October 11, 2017, 55 patients with high risk localized or locally 
advanced prostate cancer were administered definitive pelvic lymph node RT. Patients 
belonged to the elderly age group with a median [range] age of 65.60 [53.33–83.49] years, and 
they were mostly overweight showing a median [range] value of body mass index of 26.96 
[19.37–41.62] kg/m2. More than three-quarters of them had a cardiovascular co-morbidity, and 
one-third of them were smokers. All the patients had stage T2-4 N0 M0 tumour with a Gleason 
score ≥ 7 and a prostate specific antigen (PSA) level at the time of the diagnosis established > 
5 ng/ml. Most of the patients received a 6-month course of luteinizing hormone-releasing 
hormone analogue and antiandrogen (total androgen blockade, TAB) endocrine therapy, 
launched before the commencing of RT. The relevant patient and tumour characteristics are 
shown in Table 2. 
 
4.1.2 Structure volumes and rectal extension 
No significant differences were found between prone and supine positions in the volumes of 
the GTVp, GTVp+seminal vesciles, PTV, colon, small bowel, and urinary bladder. All rectal 
volumes (R, R1 and R2) were significantly higher in the prone position. The high SD values of 
mean bladder volumes in the two positioning methods might be the consequence of pre-existing 
urinary symptoms, such as incontinence. At the height of the largest AP level of the prostate, 
both the AP and the lateral rectal diameters were significantly higher in the prone position 
(Table 3). 
 
4.1.3 Rectum–prostate distance 
The rectum–prostate distance measured from the centre of the rear prostate wall to the outer 
anterior rectal wall was significantly higher in prone position. No significant differences in the 
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distance values measured from the left and right edges of the posterior prostate wall were found. 
Both intraobserver and interobserver variabilities showed close correlation (Table 4). 
 
4.1.4 Normal tissue doses 
A prone position with the additional use of a belly board led to a significant decrease in the 
absolute volumes receiving doses greater than 20 to 40 Gy in the small intestine and the colon; 
however, the difference between the volumes receiving 50 Gy was not significant (Table 5). 
In dose ranges of 40 to 75 Gy, the exposure of all rectal segments was more favourable in prone 
position. The relative volume receiving 30 Gy dose was lower in respect of R1 segment; 
nonetheless, the difference was not significant. The relative exposed volume of the urinary 
bladder, femoral heads, and bony structures was in accordance with the dose constraints. No 
significant difference was found between the positioning methods (Table 6). 
 
Tumour and patient characteristics Number of patients (%) 
Number of patients 55 
Concurrent cardiovascular disease 44 (80.00) 
History of smoking 18 (32.73) 
Clinical stages  
T2 41 (74.55) 
T3 12 (21.82) 
T4 2 (3.64) 
Gleason scores  
7 27 (48.21) 
8 5 (9.09) 
9 19 (33.93) 
10 4 (7.14) 
PSA levels on establishing the diagnosis (ng/ml)  
10>x>5 13 (23.21) 
20>x≥10 9 (16.36) 
≥20 33 (58.93) 
Endocrine treatment 49 (89.09) 
Table 2. Patient and tumour characteristics of prostate cancer patients 
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Table 3. Volumes of delineated structures and rectal diameters in prone and supine positions 
in prostate cancer patients 
4.1.5 PTV coverage 
PTV coverage did not differ significantly between the two positions (PTV D95 - mean of dose 
43.01 vs. 43.00 Gy, SD 0.26 vs. 0.26 in prone vs. supine position, respectively, p=0.782; PTVpvs 
D95 - mean of dose 13.36 vs. 13.35 Gy, SD 0.07 vs. 0.07 in prone vs. supine position, 
respectively, p=0.591; PTVp D95 - mean of dose 17.16 vs. 17.15 Gy, SD 0.09 vs. 0.07 in prone 
vs. supine position, respectively, p=0.435). 
 
Structure Position 
Mean volume 
(cm3) 
Standard 
deviation (SD) 
p value 
GTVp 
Prone 130.11 49.13 
0.217 
Supine 133.28 50.87 
GTVp + seminal 
vesicles 
Prone 188.77 58.19 
0.748 
Supine 190.23 58.20 
PTV 
Prone 1123.54 138.90 
0.282 
Supine 1130.98 146.66 
Whole rectum (R) 
Prone 155.13 105.26 
<0.001 
Supine 95.61 45.89 
Rectal subsegment R1 
Prone 50.32 31.84 
<0.001 
Supine 34.76 23.64 
Rectal subsegment R2 
Prone 74.37 41.51 
<0.001 
Supine 50.78 27.64 
Colon 
Prone 580.32 299.38 
0.486 
Supine 604.37 337.12 
Small bowel 
Prone 812.93 354.25 
0.373 
Supine 772.71 353.21 
Urinary bladder 
Prone 184.18 117.13 
0.403 
Supine 192.40 112.56 
Rectal diameter Position 
Mean 
diameter (mm) 
Standard 
error (SE) 
p value 
AP 
Prone 50.60 2.20 
<0.001 
Supine 36.70 1.50 
Lateral 
Prone 43.80 2.60 
0.003 
Supine 35.90 1.80 
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Table 4. Rectum–prostate distance and intraobserver and interobserver variability 
correlation in prone and supine positions in prostate cancer patients 
 
 
Organ At 
Risk 
DVH parameter Position 
Mean 
volume 
(cm3) 
Standard 
deviation 
(SD) 
p value 
Small 
intestine 
V20 Gy 
Prone 79.85 89.83 
<0.001 
Supine 170.34 103.62 
V30 Gy 
Prone 36.74 51.24 
<0.001 
Supine 84.55 63.01 
V40 Gy 
Prone 16.99 26.08 
<0.001 
Supine 32.91 31.35 
V50Gy 
Prone 0.16 1.06 
0.398 
Supine 0.33 1.54 
Colon 
V20 Gy 
Prone 122.43 74.52 
<0.001 
Supine 181.22 109.48 
V30 Gy 
Prone 84.09 57.17 
<0.001 
Supine 121.21 73.36 
V40 Gy 
Prone 53.23 44.20 
0.043 
Supine 63.19 44.89 
V50 Gy 
Prone 2.06 4.02 
0.627 
Supine 1.81 3.62 
Table 5. Small intestine and colon exposure in prone and supine position in prostate cancer 
patients 
 
Distance Position 
Mean 
(mm) 
Standard 
error 
(SE) 
p 
value 
Intraobserver 
variability – 
Correlation coefficient 
(r) 
Interobserver 
variability – 
Correlation 
coefficient (r) Examiner 
1 
Examiner 
2 
Left 
lateral 
Prone 6.50 0.40 
0.062 0.92 0.90 0.89 
Supine 5.70 0.40 
Medio-
sagittal 
Prone 2.80 0.30 
0.026 0.86 0.89 0.95 
Supine 2.20 0.30 
Right 
lateral 
Prone 5.90 0.40 
0.173 0.80 0.74 0.78 
Supine 5.40 0.40 
25 
 
 
OAR DVH parameter Position Mean relative V (%) SD p value 
Whole 
rectum 
V30Gy 
Prone 106.40 118.98 
0.296 
Supine 89.60 7.46 
V40Gy 
Prone 65.79 14.96 
<0.001 
Supine 78.58 10.14 
V50Gy 
Prone 35.51 13.83 
<0.001 
Supine 48.38 12.29 
V60Gy 
Prone 17.45 8.18 
<0.001 
Supine 24.04 9.11 
V70Gy 
Prone 7.57 4.10 
<0.001 
Supine 10.43 4.97 
V75Gy 
Prone 3.67 2.61 
0.021 
Supine 4.58 3.19 
Rectal 
subsegment 
R1 
V30 Gy 
Prone 99.78 0.75 
0.735 
Supine 99.80 0.61 
V40Gy 
Prone 80.58 13.50 
<0.001 
Supine 94.95 5.74 
V50Gy 
Prone 52.25 14.18 
<0.001 
Supine 68.55 10.90 
V60Gy 
Prone 32.37 10.90 
<0.001 
Supine 40.49 10.13 
V70Gy 
Prone 16.51 5.83 
<0.001 
Supine 20.74 7.14 
V75Gy 
Prone 8.79 4.52 
0.099 
Supine 9.97 5.67 
Rectal 
subsegment 
R2 
V30Gy 
Prone 99.52 1.21 
0.001 
Supine 98.61 1.96 
V40Gy 
Prone 78.55 12.66 
<0.001 
Supine 91.45 6.05 
V50Gy 
Prone 49.40 13.14 
<0.001 
Supine 64.83 9.89 
V60Gy 
Prone 28.95 9.04 
<0.001 
Supine 37.43 8.76 
V70Gy 
Prone 13.52 4.75 
<0.001 
Supine 17.86 5.79 
V75Gy 
Prone 6.82 3.59 
0.051 
Supine 7.86 4.43 
Bladder 
V30Gy 
Prone 95.82 7.10 
0.657 
Supine 95.45 5.13 
V40Gy 
Prone 67.99 18.89 
0.687 
Supine 68.78 16.13 
V50Gy 
Prone 41.90 16.53 
0.982 
Supine 41.86 14.84 
V60Gy 
Prone 26.73 11.77 
0.235 
Supine 25.36 10.62 
V70Gy 
Prone 15.91 7.90 
0.276 
Supine 14.94 7.31 
Table 6. Exposure of rectal segments and urinary bladder in prone and supine positions in prostate cancer 
patients 
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4.2 A simple clinical method for predicting the benefit of prone vs. supine positioning in 
reducing heart exposure during left breast radiotherapy 
 
4.2.1 Validation set 
In 55/100 cases, Pref was the same as Pmed while in 28 and 17 cases, Pref and Pmed differed by 1 
or more planes, respectively. More among the incorrectly defined Pref cases were shifted toward 
the caudal than the cranial direction. This resulted in smaller mean Dmed and larger mean Aheart 
values among the plane miss cases overall (Table 7). 
 All cases 
(n=100) 
Correct plane 
(n=55) 
Plane miss 
(n=45) 
 Pref Pmed Pref Pmed Pref Pmed 
Dmedian 
(cm) 
1.27±0.59 1.25±0.67 1.35±0.55 1.17±0.63 1.18±0.63 1.34±0.71 
Aheart 
(mm2) 
768.8±487.4 671.6±450.1 730.7±537.4 721.5±511.2 815.4±419.5 
610.5±358.
1 
Table 7. Dmed and Aheart values (mean±SD) as measured on Pref vs. Pmed in all cases or in 
correctly and incorrectly specified Pref cases of breast cancer patients receiving left 
breast irradiation; the measurements were performed on 2 CT scans at the middle of the 
heart either identified with the help of an AP scout view (Pref) or selected from a full CT 
series (Pmed). 
Within the whole series, no change in the frequency of plane misses could be detected by time. 
Incongruency among ΔMDLAD and ΔV25Gyheart in the supine and prone position as predicted by 
the calculator on the basis of Pref vs. Pmed data, was present in 14 and 18 of the cases, 
respectively; these were all of small numerical values (Fig. 4A, B). 
 
When the LAD and heart dose differences predicted by the calculator based on the Pref values 
were compared with the original dosimetric data from plans generated in both positions, the 
suggestion proved invalid in 14 (MDLAD) and 16 (V25Gyheart) cases (Figure 4C, D). We have 
compared the sensitivity and specificity of ΔMDLAD and ΔV25Gyheart provided by the simple 
method based on a single CT scan with that of the original method that indicated high 
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consistency [12] (Table 1). Based on these findings, the cut-off values of 0.6 Gy (ΔMDLAD) and 
1.0% (ΔV25Gyheart) have been selected for further analyses and practice. 
 
 
Figure 4. Calculator suggestion of LAD (A) and heart (B) dose differences by the input of 
Dmed and Aheart based on Pref vs. Pmed; LAD (C) and heart (D) doses according to the 
estimation of the simple clinical method based on a single CT scan vs. DVH data 
extracted from the planning system (n = 100) in breast cancer patients receiving left 
breast irradiation. Dashed lines indicate the cut-off values of 0.6 Gy (DMDLAD) and 1.0% 
(DV25Gyheart) specified by sensitivity and specificity values. 
Next, the concordance of calculator-predicted treatment position based on ΔMDLAD vs. 
ΔV25Gyheart and the need of intervention were analysed in the validation set. In 28 supine-
predicted cases and 64 prone-predicted cases, the same treatment position was suggested by 
both measures (Table 8). 
 
Among the 28 supine-predicted cases in 2, the radiotherapy plan revealed that MDLAD >12.5 
Gy, but only 1 could be improved by changing the treatment position. Among the 64 prone-
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predicted cases in 8, the MDLAD exceeded the dose constraint of 12.9 Gy; only 3 plans could be 
improved by applying the supine position. Among the discorcondant cases, ΔMDLAD suggested 
prone position in 3 and supine position in 5 cases; in both groups in a single case each could 
the LAD dose be improved by changing the treatment position. In altogether 7 cases, a different 
intervention (IMRT) had to be applied (Table 8). 
  ΔV25Gyheart 
 Supine Prone 
Δ
M
D
L
A
D 
 
All 
MDLAD 
>12.5 Gy 
change 
position 
other 
interven-
tion 
All 
MDLAD 
>12.9 Gy 
change 
position 
other 
interven-
tion 
Supine 28 2 1/2 1/2 5 1/5 1/1 - 
Prone 3 2/3 1/2 1/2 64 8/64 3/8 5/8 
Table 8. Concordance of treatment position as predicted by ΔMDLAD vs. ΔV25Gyheart, in the 
validation set (n=100) in breast cancer patients receiving left breast irradiation. In 
concordant cases the suggested position, in discordant cases the position suggested by 
ΔMDLAD was applied unless the dose constraints were exceeded; in such cases the other 
treatment position or alternative techniques may be tested. 
4.2.2 „Routine practice” set 
In the „routine practice” series of 60 patients, the new method proved feasible. All patients 
received treatment in the position suggested by the calculator except one, who had to receive a 
second CT in the other position due to unacceptable LAD dose. The other patients had MDLAD 
and V25Gyheart values well below the predefined dose limits, and these were similar to the values 
calculated in the validation set (Table 9). 
 
4.2.3 External testing 
In a series of 28 breast cancer patients from Liège, the predictors BMI, Dmed and Aheart 
significantly differed from the same parameters among the patients from Szeged. In 18/28 
cases, Pref was equal or close to Pmed (≤6 mm), while in 10 cases, Pref varied from Pmed by 9-16 
mm. Comparing the calculator-provided dose differences with the treatment planning data, 
favored treatment position was correct in 24/28 (accuracy: 85.7%) and 23/28 (accuracy: 82.1%) 
cases taking into account the LAD and heart doses, respectively. Sensitivity and specificity of 
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ΔMDLAD was 83.3% and 86.4%, respectively, whereas sensitivity and specificity of ΔV25Gyheart 
was 100.0% and 80.0%, respectively. 
 Treatment 
position 
n (%) 
mean LAD dose (Gy) V25Gy heart (%) 
mean SD min max mean SD min max 
Validation 
series 
Prone 
67 
(67.0) 
6.55 6.03 1.70 26.66 1.16 2.24 0.0 8.75 
Supine 
33 
(33.0) 
6.90 3.86 1.71 13.73 1.54 1.38 0.0 4.77 
"Routine 
practice" 
series 
Prone 
47 
(78.3) 
6.58 2.29 1.95 11.24 0.86 0.57 0.1 2.67 
Supine 
13 
(21.7) 
7.35 3.05 2.54 15.85 1.15 0.95 0.21 3.57 
Table 9. LAD and heart doses in the validation set and the „routine practice” series in 
breast cancer patients receiving left breast irradiation: in the majority of cases, LAD and 
heart doses were well below the position-related dose constraints; for those patients who 
had higher than accepted doses, an alternative technique had to be applied. 
4.3 Dosimetric comparison of 3D-CRT, sliding window IMRT and VMAT techniques for 
external beam accelerated partial breast radiotherapy 
 
4.3.1 Patient population 
The study included 138 cases. Patients belonged to the elderly age group with a median age of 
61.98 [50.11-79.71] years and the majority was postmenopausal (Table 10). In most cases 
breast cancer was diagnosed via breast screening, the mammographic examination showed 
circumscribed mass, the tumour was in the outer-upper quadrant of the breast and sentinel 
lymph node biopsy was carried out. Most cancers were invasive ductal carcinoma of grade 1-
2, hormone receptor positive and HER2-negative. The average± SD pathologic tumour size was 
11.3 ± 4.7 mm, the mean ± SD of the surgical margins was 6.8 ± 4.1 mm. The relevant patient 
and tumour characteristics are presented in Table 10. 
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4.3.2 Radiotherapy data 
The tumour bed was left-sided in 78 patients (56.5%) and right-sided in 60 patients (43.5%). 
The mean and median PTV volume was 115.6 cm3 and 108.5 (23.7-287.8) cm3, respectively. 
The PTV volume was ≥100 cm3 in 75 patients (54.3%). The distance of the geometric centre of 
the PTV from the body surface (d) was 3.6±1.6 cm (mean±SD) was less than 25 mm in 29 cases 
(21.0%). 
 
In most cases, the IMRT and VMAT techniques have given superior plans based on the PQI. 
Parameters reflecting dose distribution within the PTV and conformity are shown in Table 11. 
Based on the data represented in Table 11, in most of the cases IMRT technique is the most 
advantageous regarding homogeneity and overdosing, however, conformity is mostly improved 
by VMAT plans. OAR doses according to the technique are summarized in Table 12, while 
OAR exposure according to the side of treatment is shown in Table 12A. OAR exposures 
usually show great variety, however the mean dose to the lung and heart is the lowest 3D-CRT 
plans. These data shown in detail in Tables 11 and 12 point to the fact that traditional plan 
quality indicators per se are not suitable to choose the optimal technique in an individual case. 
 
The ’H’, ’M’ and ’P’ parameters and the PQI values generated are presented in Table 13. 
Comparing 3D-CRT, IMRT and VMAT plans on the basis of the PQID>0.05 threshold, in the 
whole cohort, the three techniques were equally good in 71 cases (51.4%). VMAT technique 
was optimal in 45 cases (32.6%), IMRT was preferable in 13 patients (9.4%) and 3D-CRT was 
the best in 9 cases (6.5%). 
When we analysed the 2 techniques based on inverse treatment planning separately on the basis 
of PQI≥0.05, the PQI was preferable using the VMAT technique in 55 cases (39.9%), while in 
14 cases (10.1%) the IMRT plan was the best. VMAT and IMRT were equally good in 69 
patients (50.0%). 
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Patient- and tumour-related characteristics 
N=138 
N % 
Menostatus   
Premenopausal (%) 17 12.3 
Postmenopausal (%) 121 87.7 
Mode of detection   
Screening (%) 109 79.0 
Symptomatic (%) 29 21.0 
Mammographic appearance (%)   
Circumscribed mass 71 51.4 
Spiculated mass 57 41.3 
Asymmetric density 7 5.1 
No abnormality 1 0.7 
Microcalcification 
(with or without a parenchymal change) 
12 8.7 
Axillary surgery (%)   
Sentinel lymph node biopsy 121 87.7 
Axillary sampling/block dissection 17 12.3 
Histological type   
Invasive ductal carcinoma not special type 116 84.1 
Invasive lobular carcinoma 2 1.4 
Invasive medullary carcinoma 1 0.7 
Invasive tubular carcinoma 9 6.5 
Invasive mucinous carcinoma 3 2.2 
Invasive papillary carcinoma 2 1.4 
Invasive mixed ductal/lobular carcinoma 3 2.2 
Invasive apocrine carcinoma 1 0.7 
Other 1 0.7 
Nottingham grade (%)   
1 52 37.7 
2 72 52.2 
3 14 10.1 
Estrogen receptor status (%)   
Positive (≥10%) 124 89.9 
Negative (<10%) 14 10.1 
Progesteron receptor status (%)   
Positive (≥10%) 115 83.3 
Negative (<10%) 23 16.7 
HER2 status (%)   
Positive 4 2.9 
Negative 134 97.1 
Adjuvant chemotherapy (%) 8 5.8 
Adjuvant endocrine treatment (%)   
Tamoxifen 10 7.2 
Aromatase inhibitor 30 21.7 
Table 10. Patient- and tumour-related characteristics of patients receiving partial breast 
irradiation 
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 Technique 
V99% V107% CN HI 
(mean±SD, 
%) 
(mean±SD, %) (mean±SD) (mean±SD) 
All cases 
3D-CRT 97.27 ± 1.46 3.51 ± 1.53 0.582 ± 0.063 0.083 ± 0.018 
IMRT 97.16 ± 1.64 0.68 ± 0.73 0.833 ± 0.081 0.045 ± 0.010 
VMAT 97.71 ± 0.87 1.45 ± 1.16 0.901 ± 0.032 0.054 ± 0.010 
PTV< 
100 cm3 
3D-CRT 97.30 ± 1.36 3.46 ± 1.51 0.585 ± 0.061 0.082 ± 0.018 
IMRT 96.85 ± 2.27 0.66 ± 0.79 0.808 ± 0.090 0.046 ± 0.011 
VMAT 97.54 ± 1.16 1.50 ± 1.33 0.900 ± 0.035 0.054 ± 0.011 
PTV≥ 
100 cm3 
3D-CRT 97.26 ± 1.55 3.56 ± 1.55 0.580 ± 0.065 0.085 ± 0.017 
IMRT 97.42 ± 0.72 0.69 ± 0.67 0.853 ± 0.066 0.044 ± 0.010 
VMAT 97.86 ± 0.46 1.40 ± 1.00 0.902 ± 0.030 0.055 ± 0.009 
d< 
2.5 cm 
3D-CRT 97.56 ± 0.75 3.86 ± 1.29 0.589 ± 0.068 0.089 ± 0.016 
3D-CRT+e 95.75 ± 2.35 4.71 ± 1.55 0.765 ± 0.071 0.082 ± 0.014 
IMRT 96.85 ± 3.20 1.07 ± 0.91 0.785 ± 0.081 0.052 ± 0.010 
IMRT+e 95.20 ± 3.42 2.87 ± 1.39 0.828 ± 0.069 0.060 ± 0.008 
VMAT 97.52 ± 1.65 2.35 ± 1.41 0.870 ± 0.037 0.064 ± 0.007 
VMAT+e 96.75 ± 2.19 3.26 ± 1.34 0.886 ± 0.048 0.065 ± 0.008 
Table 11. Partial breast irradiation according to the radiotherapy technique used: 
parameters reflecting dose distribution within the PTV and conformity 
Comparing the PQI values of patients for whom the 3D-CRT technique was the most 
advantageous to those for whom 3D-CRT was either equivalent with IMRT and VMAT, or 
worse, only the volume of the PTV emerged as significant variable (p=0.017) (Figure 5). The 
mean±SD of the PTV was 159.3±67.9 cm3 in patients for whom the 3D-CRT plan was the 
optimal, 114.4±46.3 cm3 in those for whom the IMRT technique, and 102.9±50.9 cm3 in those 
for whom VMAT was the best; the PTV was 118.3±44.8 cm3 in those patients for whom all the 
techniques gave similar PQI. Post hoc tests indicated that the PTVs were larger if the 3D-CRT 
plan was preferable (3D-CRT vs. IMRT: p= 0.035, 3D-CRT vs. VMAT: p= 0.002, 3D-CRT vs. 
IMRT/VMAT: p= 0.019). 
  
  
 Technique 
Ipsilateral breast Ipsilateral lung Heart LAD Contralateral breast Body 
V100% 
(mean±SD, 
%) 
V75% 
(mean±SD, 
%) 
V50% 
(mean±SD, 
%) 
V25% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
V40% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
V50% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
Dmax 
(mean±SD, 
Gy) 
V20% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
V10% 
(mean±SD. 
%) 
V10% rel 
to PTV 
(mean±SD) 
All 
cases 
3D-CRT 10.1±26.2 15.5±7.3 23.7±8.9 42.4±11.6 3.19±1.40 6.31±3.67 0.93±1.27 0.43±1.19 2.82±3.84 8.90±11.2 13.2±20.5 1.05±1.28 12.8±15.9 17.9±10.7 
IMRT 1.70±1.38 9.06±3.84 18.7±7.6 37.3±11.7 4.81±1.62 7.01±4.18 2.73±1.97 0.66±1.79 3.55±2.11 7.71±5.32 7.5±15.2 1.30±0.52 4.66±7.57 26.4±9.6 
VMAT 0.84±0.72 6.94±3.52 17.2±7.5 35.2±10.4 4.12±1.42 4.87±3.29 2.61±1.78 0.35±1.14 3.65±2.37 6.99±4.72 9.6±18.0 0.79±0.33 0.64±1.73 18.5±5.8 
PTV< 
100 cm3 
3D-CRT 10.5±38.6 12.0±6.1 19.8±8.2 38.1±11.7 3.23±1.43 6.52±3.51 0.95±1.36 0.39±0.96 2.86±3.75 8.11±10.5 13.5±20.6 1.25±1.33 14.4±16.1 21.6±6.5 
IMRT 1.5±1.3 7.0±2.7 14.6±5.8 31.7±10.8 4.43±1.35 6.69±3.10 2.40±1.81 0.66±1.62 3.45±2.25 7.75±5.36 8.1±15.3 1.33±0.55 6.67±8.96 33.7±8.9 
VMAT 0.5±0.4 4.9±2.3 12.8±5.7 30.8±10.2 3.71±1.13 4.41±2.13 2.29±1.64 0.31±0.91 3.48±2.14 6.80±4.54 8.7±15.7 0.80±0.33 0.65±1.15 22.3±6.0 
PTV≥ 
100 cm3 
3D-CRT 9.7±4.8 18.4±7.0 27.0±8.2 46.0±10.3 3.16±1.39 6.13±3.81 0.91±1.19 0.47±1.35 2.80±3.93 9.54±11.7 13.0±20.6 0.89±1.22 11.5±15.9 14.8±12.4 
IMRT 1.9±1.4 10.8±3.8 22.2±7.2 41.9±10.3 5.12±1.76 7.28±4.91 3.01±2.07 0.65±1.94 3.64±2.00 7.68±5.32 7.0±15.3 1.27±0.49 3.00±5.80 20.3±4.6 
VMAT 1.1±0.8 8.6±3.5 20.9±6.9 38.9±9.1 4.47±1.55 5.25±3.99 2.88±1.86 0.39±1.31 3.80±2.55 7.15±4.88 10.4±19.9 0.79±0.32 0.62±2.10 15.3±3.1 
d< 
2.5 cm 
3D-CRT 6.79±4.82 12.8±7.51 17.2±9.08 39.8±12.9 2.60±1.22 6.16±3.70 1.25±1.86 0.46±1.23 2.96±3.70 9.69±12.3 15.4±21.3 1.90±1.61 21.8±18.9 17.9±10.7 
3D-
CRT+e 
2.59±2.28 9.06±5.44 15.1±8.34 27.0±11.8 3.41±1.74 5.96±3.68 1.24±1.33 0.47±1.10 3.44±3.28 11.1±12.5 10.0±16.6 1.28±1.08 18.0±16.3 21.9±6.6 
IMRT 1.76±1.46 7.28±3.43 14.0±6.67 29.9±11.9 4.62±1.81 7.72±4.27 2.97±2.46 0.99±2.27 3.44±2.48 8.94±6.54 10.2±17.9 1.55±0.62 11.6±11.1 26.4±9.6 
IMRT+e 1.17±0.87 6.86±3.83 11.2±5.89 22.8±10.9 4.82±2.12 6.73±4.72 2.40±1.82 0.64±1.35 3.84±3.05 10.7±9.58 17.8±21.3 1.13±0.49 2.38±3.93 24.0±7.8 
VMAT 0.82±0.61 5.42±3.10 12.5±6.81 30.5±11.9 3.85±1.52 5.44±3.27 2.94±2.19 0.62±1.42 4.01±2.61 7.92±5.51 12.7±21.4 1.02±0.42 1.62±3.05 18.5±5.8 
VMAT+e 0.74±0.72 5.63±3.47 10.1±5.68 22.0±10.4 4.31±1.97 5.54±4.26 2.38±1.66 0.49±1.01 4.16±3.05 10.1±9.24 18.7±22.6 0.70±0.28 0.44±1.41 18.8±4.3 
Table 12 Partial breast irradiation according to the radiotherapy technique used: Dose to the organs at risk
  
 Technique 
Heart left-sided cases LAD left-sided cases Heart right-sided cases LAD right-sided cases 
mean 
dose 
(mean±S
D, Gy) 
V50% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
Dmax 
(mean±SD, 
Gy) 
V20% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
V50% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
Dmax 
(mean±SD, 
Gy) 
V20% 
(mean±SD, 
%) 
All 
cases 
3D-CRT 1.15±1.21 0.77±1.51 4.07±4.33 13.9±12.4 16.6±19.9 0.66±1.29 0.00±0.00 1.25±2.32 2.69±4.32 9.0±20.6 
IMRT 3.45±2.23 1.08±2.16 4.57±2.17 10.5±5.8 13.5±18.3 1.82±1.05 0.12±0.96 2.27±1.10 4.33±0.73 0.00±0.00 
VMAT 3.16±2.01 0.62±1.48 4.90±2.45 9.9±4.6 17.2±21.3 1.91±1.11 0.01±0.07 2.07±0.80 3.46±1.21 0.00±0.00 
PTV< 
100 cm3 
3D-CRT 1.06±1.08 0.68±1.20 3.84±4.20 11.7±12.3 15.0±19.4 0.81±1.68 0.00±0.00 1.54±2.58 3.62±5.07 11.4±22.2 
IMRT 3.01±2.10 0.94±1.70 4.52±2.28 10.6±5.8 14.3±18.0 1.59±0.81 0.28±1.44 2.01±1.17 4.21±0.85 0.00±0.00 
VMAT 2.73±1.90 0.52±1.16 4.58±2.14 9.5±4.3 15.3±18.3 1.70±0.94 0.02±0.11 2.01±0.92 3.37±1.47 0.00±0.00 
PTV≥ 
100 cm3 
3D-CRT 1.22±1.33 0.85±1.75 4.28±4.48 15.9±12.4 17.9±20.5 0.54±0.89 0.00±0.00 1.01±2.11 1.95±3.52 7.0±19.4 
IMRT 3.84±2.28 1.19±2.51 4.61±2.09 10.4±6.0 12.8±18.8 2.01±1.19 0.00±0.00 2.47±1.02 4.43±0.62 0.00±0.00 
VMAT 3.54±2.05 0.71±1.72 5.18±2.70 10.2±4.8 19.0±23.7 2.08±1.22 0.00±0.00 2.12±0.70 3.54±0.97 0.00±0.00 
d< 
2.5 cm 
3D-CRT 1.17±1.43 0.79±1.54 3.48±4.26 13.6±14.9 14.4±19.9 1.36±2.40 0.00±0.00 2.22±2.74 4.82±5.43 16.8±23.9 
3D-CRT+e 1.28±1.09 0.80±1.35 4.80±3.43 17.5±13.5 16.8±18.9 1.20±1.66 0.00±0.01 1.52±1.84 3.25±3.61 0.35±1.23 
IMRT 3.52±2.95 1.68±2.79 4.60±2.52 12.5±6.9 17.4±20.7 2.21±1.29 0.01±0.03 1.80±1.17 4.47±0.92 0.00±0.00 
IMRT+e 2.85±2.12 1.09±1.64 5.67±2.68 16.8±9.0 30.4±19.6 1.77±1.09 0.00±0.01 1.24±0.80 3.03±0.64 0.00±0.00 
VMAT 3.20±2.58 1.02±1.76 5.05±2.88 11.0±5.6 21.6±24.3 2.58±1.50 0.05±0.16 2.54±1.11 4.08±1.72 0.00±0.00 
VMAT+e 2.63±1.91 0.81±1.24 5.86±2.89 15.9±8.6 31.8±21.2 2.02±1.21 0.04±0.10 1.74±0.76 2.78±1.16 0.00±0.00 
Table 12A Partial breast irradiation according to the radiotherapy technique used: Dose to the organs at risk according to side of 
therapy
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 Technique 
H M P PQI 
(mean±SD) (mean±SD) (mean±SD) (mean±SD) 
All 
cases 
3D-CRT 0.598±0.067 0.768±0.069 0.654±0.160 0.595±0.127 
IMRT 0.857±0.087 0.902±0.032 0.544±0.131 0.497±0.126 
VMAT 0.922±0.035 0.868±0.054 0.571±0.128 0.461±0.125 
PTV< 
100 
cm3 
3D-CRT 0.602±0.064 0.771±0.068 0.663±0.177 0.588±0.137 
IMRT 0.836±0.098 0.901±0.035 0.591±0.120 0.464±0.115 
VMAT 0.923±0.039 0.865±0.062 0.613±0.117 0.424±0.113 
PTV≥ 
100 
cm3 
3D-CRT 0.594±0.070 0.765±0.070 0.647±0.145 0.601±0.119 
IMRT 0.876±0.072 0.903±0.030 0.505±0.127 0.524±0.129 
VMAT 0.921±0.033 0.871±0.046 0.535±0.126 0.492±0.128 
d< 
2.5 
cm 
3D-CRT 0.604±0.071 0.753±0.059 0.651±0.223 0.607±0.169 
3D-CRT+e 0.799±0.082 0.704±0.072 0.673±0.155 0.505±0.120 
IMRT 0.811±0.089 0.882±0.040 0.576±0.154 0.495±0.133 
IMRT+e 0.870±0.069 0.789±0.059 0.611±0.134 0.475±0.113 
VMAT 0.893±0.042 0.824±0.065 0.568±0.167 0.490±0.149 
VMAT+e 0.916±0.048 0.778±0.059 0.611±0.136 0.467±0.118 
Table 13 The (H)ealthy tissue conformity, the (M)erit function, the (P)enalty function and the 
PQI according to technique in patients receiving partial breast irradiation 
Comparing the inverse planning techniques (IMRT and VMAT) only, the use of the IMRT 
method gave superior plans in case of superficially located tumour beds (p<0.001) (Figure 6) 
and if the target volumes were located in the medial/central (p<0.032) or upper quadrants 
(p<0.046) of the breast (Table 14). 
In case of superficially located PTVs (d<25 mm, 29 patients) the effect of the addition of an 
electron beam was analysed for all the techniques (3D-CRT, IMRT and VMAT). Two-way 
repeated measures ANOVA revealed that the magnitude of the effect of adding an electron 
beam depends on the chosen technique (significant interaction, p<0.001). Although the addition 
of an electron beam improved the PQI of all treatment plans, its extent was relevant (PQI>0.05) 
only in the 3D-CRT plans, but not in the IMRT or VMAT plans (Table 15, Figure 7). 
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Figure 5 Comparison of PQI values of those patients receiving partial breast irradiation for 
whom 3D-CRT was the most advantageous, 3D-CRT was equivalent with IMRT or VMAT, 
IMRT and VMAT were equivalent but superior to 3D-CRT, IMRT was the most favourable 
and finally VMAT was the most favourable plan, depending on the volume of the PTV 
 
 
Radiotherapy technique 
[n (%)] 
 
Radiotherapy technique 
[n (%)] 
IMRT 
better 
Equiva-
lent 
VMAT 
better 
IMRT 
better 
Equiva-
lent 
VMAT 
better 
Q
u
a
d
ra
n
t 
Lateral 
4 
(28.6%) 
44 
(63.8%) 
36 
(65.5%) 
Lower 
0 
(0%) 
21 
(30.4%) 
12 
(21.8%) 
Medial/
central 
10 
(71.4%) 
25 
(36.2%) 
19 
(34.5%) 
Upper 
14 
(100%) 
48 
(69.6%) 
43 
(78.2%) 
Table 14 The more advantageous radiotherapy technique in relation to the location of the 
target volume in patients receiving partial breast irradiation 
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Figure 6 PQI was superior with IMRT in cases with superficially located target volumes than 
with VMAT in patients receiving partial breast irradiation 
 
 
Mean ± SD of 
PQI 
PQID 
95% 
Confidence 
interval for 
PQID 
p 
IMRT 0.495 ± 0.025 
0.020 0.000-0.039 0.055 
IMRT + electron 0.475 ± 0.021 
VMAT 0.490 ± 0.028 
0.023 0.002-0.045 0.037 
VMAT + electron 0.467 ± 0.022 
3D-CRT 0.607 ± 0.031 
0.102 0.070-0.133 <0.001 
3D-CRT + electron 0.505 ± 0.022 
Table 15 Mean differences of PQI values regarding the effect of adding an ‘en face’ electron 
beam to photon beams using IMRT, VMAT and 3D-CRT techniques in patients receiving 
partial breast irradiation 
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Figure 7 The effect of adding an ‘en face’ electron beam to photon beams on IMRT, VMAT 
and 3DCRT plans in patients receiving partial breast irradiation as depicted on a profile 
figure 
In 67 cases with PQI differences >0.05, we analysed which components (H, M and P function) 
were the primary determinants of PQI according to the three radiotherapy techniques. We found 
that the best PQI value of a case was primarily dependent on the P function representing OAR 
exposure. This function was the strength of the few (n=9) 3D-CRT-preferred cases with a 
relatively large PTV (mean: 159.3 cm3, range: 81.3-287.8 cm3) (Figure 8). 
Figure 8 Representation of the effect of the components of the PQI according to the 
preferable plan (IMRT, VMAT or 3D-CRT) in patients receiving partial breast irradiation  
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5 Discussion 
 
5.1 Prone positioning on a belly board decreases rectal and bowel doses in pelvic IMRT for 
prostate cancer 
 
Clinically localized high-risk prostate cancer frequently shows micrometastatic spreading to the 
pelvic lymph nodes; therefore, RT and three years of androgen suppressing endocrine treatment 
are the standard of care. Dose escalation to the prostate even to 80–86.4 Gy reduces biochemical 
failure and the appearance of distant metastases [21]. However, survival data are controversial 
regarding field size [21]. There is no consensus recommendation for patient selection for pelvic 
RT in this population, considering the increased exposure of OARs and toxicity. 90% of patients 
treated with pelvic RT develop permanent alterations in bowel habits [22], 50% of them 
complain about adverse changes in life quality [23], and 20–40% of them assess this impact as 
moderate or severe [24]. The small intestine, the rectum, and to a lesser extent, the colon are 
dose-limiting organs, tolerating a 50–60 Gy dose at conventional fractionation [25,26]. Normal 
tissue complication probability (NTCP) studies suggest that the small intestine volume 
receiving 15 and 45 Gy (V15Gy and V45Gy) is a relevant parameter for GI morbidity [27,28]. 
According to the review of Fiorino et al. [29], keeping V70Gy and V75Gy to <25% and <5%, 
respectively, results in a decrease in the development of late rectal bleeding. Moderate dose 
volumes, such as V40Gy and V50Gy are predictive for chronic late incontinence [30] and are also 
important in developing rectal bleeding [29,30]. The dosimetric analysis [31] of the anatomical 
subregions showed that rectal bleeding is associated with V70Gy of the anorectal region, fecal 
incontinence with V15Gy of external sphincter, and V55Gy of the iliococcygeal muscle, whereas 
stool frequency with V40Gy of the levator ani and V45Gy of the iliococcygeal muscle. In the 
prospective study of Dréan et al. [32], rectal subregions at risk have been delineated, and the 
authors have found that the exposure of the subprostatic anterior hemirectum and the upper part 
of the anal canal was 4 Gy higher in patients developing rectal bleeding. 
 
Technological advances allowing rectal sparing include the use of endorectal balloons filled 
with air or water, reducing the exposure of the posterior rectal wall by moving away the prostate 
from it, depending on the volume of the balloons [33]. Bioabsorbable tissue spacers injected 
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into the retroprostatic fascia also increase the distance between the prostate and the anterior 
rectal wall, resulting in significant reduction in both acute and late GI toxicities [34]. Regarding 
patient positioning, Zelefsky et al. [35] and McLaughlin et al. [36] have described significantly 
lower rectal doses in the prone position, using 3D-CRT technique. The results have also been 
confirmed in the phase II trial of O’Neil et al. [37] and by Bajon et al. using tomotherapy [38]. 
Nevertheless, Baylay et al. [39] have found supine position more favourable by using larger 
PTV margins in prone position, and Kato et al. [40] by applying IMRT in supine and 3D-CRT 
in prone position. In prone position, the decreased rectal exposure is a result of the posterior 
retraction of the rectum and anterior displacement of the prostate; however, the accurate 
mechanism of it is unknown [35, 36, 40]. 
 
In 3D-CRT of rectal malignancies, the prone treatment position even without a belly board 
results in the reduction of the irradiated small intestine volume as compared to the supine 
posture [41]. In case of pelvic malignancies, a larger decrease in the small intestine exposure 
can be obtained by the additional use of a belly board in comparison with both prone position 
alone [42,43] or supine position [44,45]. The use of IMRT technique decreases bowel doses by 
40–50%, as compared to 3D-CRT [46,47]. In case of gynecological and rectal tumours, a belly 
board-assisted prone position using IMRT results in a further reduction in the irradiated volume 
of the small intestine, even in the low dose areas [48,49]. The advantage of the use of a belly 
board is also confirmed in postoperatively irradiated patients [50,51], which might be the 
consequence of the significantly higher mobilization of the small intestine loops. The findings 
of Fu et al. [52] show that the gain of the use of a belly board is greater if the irradiated small 
intestine volume close to the target volume is larger. According to that study, a prone position 
on a belly board results in a remarkable decrease in the small bowel volume in case of 
gynecological malignancies but not in rectal cancer patients. A full bladder also functions as a 
natural spacer, transposing the small intestine loops from the pelvis to the abdomen, resulting 
in a reduction in the irradiated small intestine volume [50]. 
 
In rectal cancer patients treated with chemo-radiotherapy, Baglan et al. [27] have demonstrated 
an explicit relationship between the volume of the small bowel receiving at least 15 Gy and the 
degree of acute small intestinal toxicity. Robertson et al. [53] have proved that a reduction in 
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the small bowel volume receiving low dose results in a significant decrease in the complication 
rate. Both authors have delineated the single small intestinal loops. In case of gynecological 
cancer patients treated with pelvic IMRT, Roeske et al. [28], contouring the peritoneal cavity, 
have detected that the risk of acute gastrointestinal toxicity is five times as little for small bowel 
volume of 100 cm3 gaining the prescribed 45 Gy dose as of 200 cm3. According to 
Gunnlaugsson et al. [54], the delineation of single small intestinal loops is the recommended 
contouring method instead of delineating the peritoneal cavity, as they have observed strong 
correlation between the occurrence of early side effects and small intestinal loop exposure, and 
no significant connection with the peritoneal cavity. 
 
Our study was limited by the lack of delineating the penile bulb, and the relatively small number 
of patients involved, which however was double the number of patients previously reported. As 
most papers have described larger intrafraction prostate motion in prone position [8] and 
literature data [55] show that a 3 mm PTV margin allows for CTV to be covered for 99% of 
cases when daily CBCT is used, accurate patient repositioning, daily reconstruction of the 
rectum, prostate safety margins, early toxicity and life quality during and after RT were also 
evaluated, and found to be similar to literature data of patients treated in supine position [56]. 
Late toxicities need further examination due to the short follow-up period. 
5.2 A simple clinical method for predicting the benefit of prone vs. supine positioning in 
reducing heart exposure during left breast radiotherapy 
 
According to the present study and others [12,57-60], in about 20% of the cases, prone 
positioning during left breast radiotherapy increases the dose to the LAD or the heart. To 
estimate and select the preferable positioning mode, supine CT seems the best approach to 
consider the patient’s anatomical determinants. We have shown that a single CT scan at the 
middle of the heart may replace a whole CT series by providing consistent anatomical data thus 
avoiding extra radiation exposure to the patient and work load to the staff. Based on the outcome 
of the external validation of the method on an independent case series, we recommend its use 
after local testing. 
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Our validated statistical model for predicting the preferable treatment position utilizes 3 specific 
measures and seems the most complex predictive tool for this purpose in the literature [12]. In 
other studies, the in-field heart volume [61-63] and most frequently the size of the breast [3,57] 
have been used for selection. Increased BMI has also been related to larger heart doses [64] or 
consequential radiation cardiac morbidity [65], but its role in predicting benefit of prone 
positioning may be refined by the use of other patient-related parameters [12]. We consider the 
BMI in our calculator as a stable parameter while there is potential uncertainty in the 
specification of Pref or imprecision in the actual measurement of Dmedian or Aheart on a given 
image. Nevertheless, detailed analysis indicates that accidental imprecision does not 
significantly influence final prediction (data not shown). The dose constraints optimized by 
individual positioning provides additional safety in practice. Despite the lack of full equivalence 
of the data extracted from the original method vs. the new method, the ultimate consistency still 
seems to qualify the developed „simple tool” for clinical application. 
 
External validation indicated similar accuracy as the originally developed method. Despite the 
reassuring results of the validation on an independent series of patients in a radiotherapy centre 
using a slightly different protocol, the utility of the reported clinical tool could be compromised 
by the diversity of practice in others. PTV contouring depends on repositioning accuracy and 
the method of treatment verification. Interfractional differences may be especially large in the 
prone position [13,66]. Lakosi et al. found population systematic error values of 4.5/3.9/3.3 mm 
in the lateral/longitudinal/vertical directions, while the random error was 5.4/3.8/2.8 mm [15]. 
Among our recent prone breast radiotherapy cases, the population systematic and random error 
in the lateral/longitudinal/vertical directions was 3.4/2.3/2.7 mm and 7.8/4.6/6.9 mm, 
respectively. Only some groups study the dose to the coronary arteries [12,54,60,67-70]. The 
outlining of the coronary vessels shows significant inter-observer variation that may jeopardize 
dose verification in the selected position. [16,71]. Different approaches have been tested to 
improve consistency including the administration of contrast media [16,71,72]. Lee et al. 
developed a new protocol to outline the LAD region which included 96% of the LAD volume 
as delineated by 4 experienced radiation oncologists [72]. Significant impact was made by the 
implementation of specific guidelines [16,71,72]. Since the utility of the simple tool might be 
influenced by several factors, we consider essential its testing before routine use. 
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The benefit of positioning prone vs. supine may be discordant by means of LAD and heart doses 
[12,57,70]. We regard the LAD dose as a surrogate indicator of radiation harm due to its proven 
role in late cardiac morbidity [2] and because the LAD being situated on the anterior surface of 
the heart is a sensitive marker of danger if the heart is at all included into radiation. Our strategy 
for optimization in individual cases is to consider the MDLAD as priority that is usually 
confirmed by the heart dose (as was true for 92% of cases in our series). 
 
The radiation exposure of the heart may be significantly reduced by the use of respiration-
guided techniques including the deep inspiration breath hold (DIBH) technique and respiratory 
gating. In the UK HeartSpare study, supine DIBH provided superior cardiac sparing than a free-
breathing prone position in larger-breasted women [67]. Interestingly, the implementation of 
DIBH in the prone position gave the optimal heart sparing results as compared with that in the 
supine position or free-breathing [68]. There are some centres that due to resource limitations 
prioritise high cardiac dose cases for DIBH [73]. Our tool could be used for patients either not 
amenable for or not having access to DIBH due to patient-specific features or limited/no 
resources. 
 
We think that since a linear, no-threshold association exists between the mean heart dose and 
coronary events [2], doses to the LAD, right coronary artery or the circumflex artery should be 
controlled [60]. Nevertheless, the utilization of heart dose-volume data only is a possibility if 
LAD contouring can not be afforded. Since good agreement exists between the mean heart dose 
and V25Gyheart (Rprone: 0.98, Rsupine: 0.99) or MDLAD (Rprone and Rsupine: 0.87) in both 
positions (p<0.001 in all comparisons), the here presented tool could be adapted to practices 
which adher to the consideration of the mean heart dose. 
 
5.3 Dosimetric comparison of 3D-CRT, sliding window IMRT and VMAT techniques for 
external beam accelerated partial breast radiotherapy 
In selected early breast cancer cases, APBI is an attractive treatment alternative to whole breast 
irradiation by shortening the course of RT and reducing radiation exposure of healthy tissues 
significantly [6,74,75]. Various teletherapy techniques have been studied for APBI with 
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different dosimetric specialities [76-82]. Our findings indicate that IMRT, VMAT or 3D-CRT 
may be individually superior in at least half of the cases; by selecting the most advantageous 
APBI method, dose homogeneity and OAR exposure could be optimised. The here described 
PQI that takes into account both homogeneity, conformity and dose to various OARs may serve 
as a comprehensive tool for comparing teletherapy APBI plans. 
Many studies analysed the dosimetry of inverse-planning techniques over standard 3D-CRT 
[83-88]. The use of IMRT or VMAT improved conformity in all studies, and in most of them 
selected OARs’ exposure as well. With the use of IMRT, the reduction of the dose to the 
ipsilateral breast [84,85], lung and heart [85] was achieved as compared to that of 3D-CRT 
plans. In the study of Rusthoven et al. [85], the ipsilateral breast dose was especially more 
favourable with IMRT than with 3D-CRT in cases with larger PTV/breast ratio and smaller 
breasts. Interestingly, we found altogether 9 cases out of 138 with relatively larger PTVs, in 
which 3D-CRT provided the best PQI probably due to the formula’s complexity. Using the 
VMAT technique, the dose to the lung and heart was lower than that with 3D-CRT [89]. Qiu et 
al. [87] performed a dosimetric analysis of 16 VMAT vs. IMRT vs. 3D-CRT plans. The dose 
(V5Gy, V10Gy) to the ipsilateral breast was significantly lower with VMAT than the other 2 
techniques. Heart exposure was similar among the three techniques while lung dose was 
superior with IMRT and VMAT than with 3D-CRT; IMRT provided the most favourable low-
dose distribution in the ipsilateral lung [87]. 
Stelczer et al. [88] compared the step and shoot and sliding window IMRT methods and the 
VMAT technique to the 3D-CRT technique based on various dosimetric parameters and the 
original PQI approach [19] in 10 low-risk breast cancer cases. While dose homogeneity was 
superior using the sliding window IMRT, in accordance with our results, ipsilateral breast 
exposure was significantly lower with VMAT, and the protection of the lung and heart was the 
best with 3DCRT [88]. V50% of the ipsilateral breast was the lowest in VMAT plans (29.4%), 
as compared to 3D-CRT (44.1%) and sliding window IMRT (35.6%) plans. As a consequence, 
they recommend the use of sliding window IMRT for APBI [88]. 
The addition of electrons to photon beams provides more conformal but less homogenous dose 
distribution as compared to the photon only technique. We have found five studies dealing with 
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the mixed beam technique in APBI [83,90-93]. All agreed that this approach may lower the 
ipsilateral breast dose; lung and heart doses varied according to study, and obviously the 
situation of the tumour bed [92]. Clearly, the use of electrons should be reserved for tumours 
non-deeply located [94]. In the present study, the addition of a shaped electron field to 3D-CRT 
provided benefit in cases with d<25 mm. We believe that this method could be recommended 
if due to limitations of resources or technology 3D-CRT were utilized for APBI. 
In selected cases, APBI provides similar efficacy and less toxicity versus whole breast 
irradiation with probably better cosmesis and acceptance by the patients [95,96]. Most 
prospective phase II and phase III studies utilizing 3D-CRT technique for APBI have reported 
favourable early and late side effect profile, good or excellent cosmetic results and quality of 
life comparable to that with whole breast irradiation [79,96-99]. Likewise, excellent outcome 
was reported in studies with IMRT [81,82]. Nevertheless, in some APBI studies implementing 
the IMRT [80,100] or 3D-CRT method [101,102] progressive breast fibrosis and poor cosmetic 
outcome was reported. In the most recently reported RAPID trial, more fibrosis and 
progressively deteriorating cosmetic outcome was found after APBI with 3D-CRT/IMRT than 
after whole breast radiotherapy [103]. All these studies applied similar doses as the other 
teletherapy APBI trials, but in an accelerated manner (dosing twice daily). Impaired cosmetic 
results following 3D-CRT or IMRT APBI could have been also due to the irradiation of larger 
target volumes and more extensive ipsilateral breast tissue as well. The detrimental effect of 
large irradiated volumes on fibrosis-related poor cosmesis had been described in the 1990s 
[104]. Based on our results, if ipsilateral breast dose is a concern we propose the VMAT 
technique, or if 3D-CRT is to be utilised, the addition of electrons. 
Our study suggests that while dose coverage and acceptable homogeneity may be ensured by 
any of the studied techniques, the main differences may be detected in OAR exposure in about 
50% of the cases. Namely the dose to the heart and LAD and the success to limit the radiation 
dose to the ipsilateral breast much depend on the selected method. For the evaluation of 
different techniques, different measures have been used in the literature. Most of the studies 
compared various dose-volume parameters, OAR exposure, maximum doses, coverage or more 
complex indexes such as conformity index, conformation number, homogeneity index or the 
PQI which we used [19]. All parameters carry different meanings, but if used singly, 
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comparisons are difficult. This is why we aimed at following a comprehensive approach which 
is based on the simultaneous consideration of various factors such as homogeneity, conformity 
and OAR protection. Since in our study conformity and homogeneity did not differ as 
significantly as OAR exposures in the different plans (Figure 8), PQID mainly depended on 
which technique ensured the best comprehensive OAR protection. The strength of our method 
is that we based it on a relatively large and comprehensive data set. 
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6 Summary, conclusions 
 
6.1 During pelvic IMRT in prostate cancer, prone positioning on a belly board decreases 
the irradiated small bowel volumes even in the low dose ranges and contributes to rectal sparing. 
The relative dose reduction in the rectal exposure might be a consequence of the slightly 
increasing distance between the prostate wall and the rectal wall, and the increasing volume 
and diameters of the rectum generated by the displacement of rectal gases. Considering the 
dosimetric advantages, prone position on a belly board is recommended for pelvic IMRT in 
prostate cancer. 
 
6.2 Great consistency of our method based on a validated model for the prediction of 
treatment position prone vs. supine with less heart exposure during left breast RT has been 
demonstrated; the simplified tool presented here omits the performance of planning CT in both 
positions. Based on the results of its external validation, we truly recommend its use in centres 
that apply prone positioning in routine practice. 
 
6.3 PQI is a good tool to evaluate external beam APBI plans. In most cases, IMRT and 
especially VMAT plans give superior PQI values than 3D-CRT plans. 3D-CRT may be 
favourable in cases with large PTV. In superficially situated tumour beds the addition of an 
electron beam results in significant PQI improvement of 3D-CRT plans. Comparing the IMRT 
and VMAT methods, IMRT seems superior in tumours of the superior or inner quadrant of the 
breast. PQI is primarily dependent on OAR exposure. 
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Abstract
The presence of normal tissues in the irradiated volume limits dose escalation during pelvic radiotherapy (RT) for prostate cancer.
Supine and prone positions on a belly board were compared by analyzing the exposure of organs at risk (OARs) using intensity
modulated RT (IMRT). The prospective trial included 55 high risk, localized or locally advanced prostate cancer patients,
receiving definitive image-guided RT. Computed tomography scanning for irradiation planning was carried out in both positions.
Gross tumor volume, clinical and planning target volumes (PTV) and OARs were delineated, defining subprostatic and
periprostatic rectal subsegments. At the height of the largest antero-posterior (AP) diameter of the prostate, rectal diameters
and distance from the posterior prostate wall were measured. IMRT plans were generated. Normal tissue exposure and structure
volumes were compared between supine and prone plans using paired t-test. In the volumes of the prostate, PTV, colon and small
bowel, no significant differences were found. In prone position, all rectal volumes, diameters, and rectum–prostate distance were
significantly higher, the irradiated colon and small bowel volume was lower in dose ranges of 20–40 Gy, and the exposure to all
rectal segments was more favorable in 40–75 Gy dose ranges. No significant difference was found in the exposure of other
OARs. Prone positioning on a belly board is an appropriate positioning method aiming rectum and bowel protection during
pelvic IMRTof prostate cancer. The relative reduction in rectal exposure might be a consequence of the slight departure between
the prostate and rectal wall.
Keywords Prostate cancer . IMRT . Prone . Belly board . Small bowel . Rectum
Introduction
Prostate cancer is the second most common malignancy
worldwide [1]. Its prognosis has improved as a result of
adjuvant androgen deprivation therapy and the escalated
dose, and the efficacy of radiotherapy (RT) [2].
Therefore, pelvic irradiation including the prostate, sem-
inal vesicles, and lymphatic regions is an integral com-
ponent of high-risk [3], organ-confined, and locally ad-
vanced prostate cancer management.
Although RT is getting more targeted, the tolerance of nor-
mal tissues limits dose escalation and tumor control probability,
and makes the incidence of acute and chronic gastrointestinal
(GI) morbidity higher, aggravating the co-existing urological,
sexual, and psychological problems of the increasing number
of cancer survivors [4]. The phenomena of GI injury secondary
to RTare described as pelvic radiation disease (PRD) [5]. Acute
PRD, occurring during or shortly after RT, presents in abdom-
inal–anorectal pain, lack of appetite, nausea, vomiting,
bloating, diarrhea, and rectal bleeding. Chronic complications
developing between 1.5 and 6 years after the completion of
pelvic RT may manifest as anorexia, lactose intolerance, mal-
absorption, fistula formation, bowel obstruction, perforation,
and fecal incontinence [6]. The symptoms depend on the de-
gree and extent of the tissue damage [7] and have a significant
adverse effect on the patient’s quality of life [8]. The most
important factors related to the probability of the complications
are the total dose of RT delivered to the pelvic organs, the
applied regime, the size of the treatment fields, the presence
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of radiation implants, concurrent chemotherapy, and the vol-
ume of the bowel irradiated [7].
The irradiated bowel volume can be minimized by surgical
and non-surgical methods [9]. Surgical means include pelvic
reconstruction, reperitonealization of the pelvic floor, place-
ment of an omental sling, and the inserting of a synthetic pros-
thesis under the small intestine. Radiotherapeutic techniques
embrace among others the use of intensity modulated (IM)
and image-guided (IG) RT, adaptive irradiation, a shrinking
field, modified fractionation schemes, endorectal balloons, tis-
sue spacers, bladder distension, and optimal patient position.
The purpose of our study was to assess whether a supine or
prone position on a belly board, applying IMRT technique,
results in the reduction of the radiation dose to organs at risk
(OARs), primarily the rectum, colon, and small intestines dur-
ing pelvic RT of prostate cancer patients.
Materials and Methods
Patient Population
The prospective analysis included patients with a histologically
confirmed, high risk [10], localized or locally advanced (2009
TNM classification [11] stage T2–4 N0–1 M0) prostate cancer
graded according to the Gleason score system [12], receiving a
definitive pelvic RT at the Department of Oncotherapy,
University of Szeged, Hungary. The tumor stage assessment
was based on the findings of thoracic computed tomography
(CT), abdominal and pelvic CT and magnetic resonance imag-
ing (MRI), and whole-body bone scintigraphy. Clinical and
pathological data were extracted from the patient files.
Patient Positioning and Computed Tomography
Scanning
Patients were positioned on the supine and prone pelvis mod-
ules of the All in One (AIO) Solution (ORFIT, Wijnegem,
Belgium) system. In supine pose, the patient was positioned
with bent knees, and the genitalia were distracted with extrud-
ed polystyrene blocks. In prone position, a belly board was
applied to allow the abdomen to extend into its aperture, and a
polystyrene wedge was placed between the buttocks. For im-
mobilization a six-point thermoplastic mask fixation
(Pelvicast system, ORFIT, Wijnegem, Belgium) was
employed. All patients underwent five-millimeter slice-incre-
ment topometric CT scanning in both positions from the dia-
phragm to the level of 10 cm below the femoral necks, using a
Somatom Emotion 6 CT Simulator (Siemens, Erlangen,
Germany). CT scanning was prepared with full bladder ac-
cording to our internal protocol, and following an antiflatulent
diet for at least 7 days prior and during RT delivery.
Target and Critical Structure Delineation
The gross tumor volume (GTV), clinical target volume
(CTV), planning target volume (PTV), and OARs were delin-
eated in the ARIA Oncology Information System (Varian
Oncology Systems, Palo Alto, CA, USA) in both positions
by radiation oncologists and reviewed by an experienced ra-
diologist. The prostate was contoured as GTVp, the proximal
thirds, or in case of involvement, the full extension of the
seminal vesicles were contoured as GTVvs, and pathologic
lymph nodes, if present, as GTVN, considering MRI records.
CTVN included the parailiac, upper subaortic presacral and
obturator lymph nodes, contoured according to the RTOG
GU Radiation Oncology Specialists Reach Consensus [13].
PTVp included GTVp with a 10 mm margin along the
supero-inferior, left–right axis, in anterior direction and
7 mm in posterior direction. PTVpvs was defined as the com-
bination of GTVp and GTVvs with a safety margin of 10 mm
and 15 mm in posterior direction and any other directions,
respectively. PTV was determined as PTVpvs, a 7 mm margin
around CTVN and 10 mm around GTVN, if present. The rec-
tum, large and small intestines, urinary bladder, femoral
heads, and bony structures were outlined as OARs. The rec-
tum was defined from the ischial tuberosities to the sigmoid
flexure, but at least 2 cm above PTVpvs. Each rectal section,
the whole rectum (R), the segment at the height of the prostate
(R1), and R1 + 10 mm along the supero-inferior axis (R2)
were individually delineated. Large and small bowel volumes
contained all identifiable segments. The bladder was delineat-
ed from the apex to the dome [14].
Rectal Extension and Rectum–Prostate Distance
Measurement
At the height of the largest antero-posterior (AP) diameter of
the prostate, rectal diameters along the AP and left–right axis
were defined, and perpendicular lines were created from the
center and lateral edges of the back wall of the prostate to the
outer anterior rectal wall in both supine and prone positions
(Fig. 1). Two independent radiation oncologists performed
rectum–prostate distance measurements, both of them twice.
Intensity-Modulated Radiotherapy Planning
and Dosimetric Analysis
IMRT planning was performed using the Eclipse treatment
planning system (Varian Oncology Systems, Palo Alto, CA,
USA). The prescribed doses were 45 Gy to the center of the
PTV (1.8 Gy/day, 5 days/week), 14 Gy of the PTVpvs and
18 Gy of PTVp, both delivered in daily 2 Gy fractions, 5 days
per week. OAR dose constraints were determined as the fol-
lowing [13]: V55Gy (bladder) ≤ 50%, V70Gy (bladder) ≤ 30%; V50Gy
(rectum) ≤ 50%, V70Gy (rectum) ≤ 20%; V50Gy (colon) ≤ 50%, V70Gy
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(colon) ≤ 20%; V52Gy (small intestine) = 0%; V50Gy (femoral heads) <
5%. For the coverage of the PTV sliding window IMRT plans
were designed in both positions with a seven-field beam ar-
rangement using 6 MV photon beam quality, consisting copla-
nar beam directions as the following: in prone position 0°,
136.1°, 208.3°, 258.7°, 101.7°, 306.1° and 55.2°, in supine
position 0°, 38.2°, 98°, 142°, 215.7°, 269.5° and 318.2°. For
the PTVpvs and PTVp volumetric modulated arc therapy
(VMAT) plans were generated in both positions using 6 MV
photon beam quality, 181°–179° and 179°–181° gantry angles
and 30° and 15° collimator angles, respectively. IMRT plans
were created to obtain a 95% coverage of the PTV with the
95% isodose curve. The highest priority was PTV coverage,
and the second one was the sparing of OARs. Planning assis-
tant contours of the PTV, PTVpvs, and PTVp were designed
with uniform margins of 15 mm, 30 mm, 40 mm, and 50 mm
in both positions. Dose-volume histograms were calculated for
all defined volumes. Data of mean volumes of the contoured
structures, mean absolute volumes of the small bowel and co-
lon receiving 20–50 Gy, mean relative volumes of the rectal
segments receiving 30–75 Gy and of the bladder receiving 30–
70 Gy doses and mean of doses regarding PTV D95, PTVpvs
D95, and PTVp D95 were collected.
Radiation Treatment and Image-Guidance
Irradiation was carried out by using a Varian TrueBeamSTx
(Varian Oncology Systems, Palo Alto, CA, USA) in prone po-
sition. Image-guidance was based on daily kV-cone beam CT
(CBCT) scanning of the pelvis prior to treatment, using the
standard mode settings: 125 kV, 80 mA, 13 ms, and half-fan
bowtie filter. An automatic match algorithm was used to match
the bony structures displayed on the planningCTand theCBCT.
Statistical Analysis
Data were reported as mean ± SD, mean ± SE or median
values. The difference between the volumes and doses in
supine and prone position was analyzed with the paired sam-
ples t-test. Intraobserver and interobserver variabilities were
calculated from the mean of distances by using correlation
analysis, given a correlation coefficient (r). SPSS 20.0 for
Windows (SPSS Inc., Chicago, IL, USA) was used to perform
the analysis. A p value <0.05 was considered significant.
Results
Patient Population
Between October 13, 2016 and October 11, 2017, 55 patients
with high risk localized or locally advanced prostate cancer
were administered definitive pelvic lymph node RT. Patients
belonged to the elderly age group with a median [range] age of
65.60 [53.33–83.49] years, and they were mostly overweight
showing a median [range] value of body mass index of 26.96
[19.37–41.62] kg/m2. More than three-quarters of them had a
cardiovascular co-morbidity, and one-third of them were
smokers. All the patients had stage T2–4 N0 M0 tumor with
a Gleason score ≥ 7 and a prostate specific antigen (PSA) level
at the time of the diagnosis established >5 ng/ml. Most of the
patients received a 6-month course of luteinizing hormone-
releasing hormone analogue and antiandrogen (total androgen
blockade, TAB) endocrine therapy, launched before the com-
mencing of RT. The relevant patient and tumor characteristics
are shown in Table 1.
Structure Volumes and Rectal Extension
No significant differences were found between prone and su-
pine positions in the volumes of the GTVp, PVS, PTV, colon,
small bowel, and urinary bladder. All rectal volumes (R, R1
and R2) were significantly higher in prone position. The higher
SD values of mean bladder volumes in the two positioning
methods might be the consequence of pre-existing urinary
symptoms, such as incontinence. At the height of the largest
Fig. 1 Rectal extension and rectum–prostate distance measurement: At
the height of the largest antero-posterior diameter of the prostate perpen-
diculars were created from the center and both lateral edges of the
posterior prostate wall to the anterior rectal wall in both prone (a) and
supine (b) positions. Larger rectal diameters in prone, smaller in supine
position in case of the same patient at the same time
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AP level of the prostate, both the AP and the lateral rectal
diameters were significantly higher in prone position (Table 2).
Rectum–Prostate Distance
The rectum–prostate distance measured from the center
of the rear prostate wall to the outer anterior rectal wall
was significantly higher in prone position. No signifi-
cant differences in the distance values measured from
the left and right edges of the posterior prostate wall
were found. Both intraobserver and interobserver vari-
abilities showed close correlation (Table 3).
Normal Tissue Doses
A prone position with the additional use of a belly board led to
a significant decrease in the absolute volumes receiving doses
greater than 20 to 40 Gy in the small intestine and the colon;
however, the difference between the volumes receiving 50 Gy
was not significant (Table 4). In dose ranges of 40 to 75 Gy,
the exposure of all rectal segments was more favorable in
prone position. The relative volume receiving 30 Gy dose
was lower in respect of R1 segment; nonetheless, the differ-
ence was not significant. The relative exposed volume of the
urinary bladder, femoral heads, and bony structures was in
accordance with the dose constraints. No significant differ-
ence was found between the positioning methods (Table 5).
Planning Target Volume Coverage
PTV coverage did not differ significantly between the two
positions (PTV D95 - mean of dose 43.01 vs. 43.00 Gy, SD
0.26 vs. 0.26 in prone vs. supine position, respectively, p =
0.782; PTVpvs D95 - mean of dose 13.36 vs. 13.35 Gy, SD
0.07 vs. 0.07 in prone vs. supine position, respectively, p =
0.591; PTVp D95 - mean of dose 17.16 vs. 17.15 Gy, SD 0.09
vs. 0.07 in prone vs. supine position, respectively, p = 0.435).
Discussion
Clinically localized high-risk prostate cancer frequently
shows micrometastatic spreading to the pelvic lymph
nodes; therefore, RT and three years of androgen suppress-
ing endocrine treatment are the standard of care. Dose es-
calation to the prostate even to 80–86.4 Gy reduces bio-
chemical failure and the appearance of distant metastases
[2]. However, survival data are controversial regarding field
size [2]. There is no consensus recommendation for patient
selection for pelvic RT in this population, considering the
increased exposure of OARs and toxicity. 90% of patients
treated with pelvic RT develop permanent alterations in
bowel habits [8], 50% of them complain about adverse
changes in life quality [15], and 20–40% of them assess
this impact as moderate or severe [16]. The small intestine,
the rectum, and to a lesser extent, the colon are dose-
Table 1 Patient and tumor characteristics
Tumor and patient characteristics Number of patients (%)
Number of patients 55
Concurrent cardiovascular disease 44 (80.00)
History of smoking 18 (32.73)
Clinical stages
T2 41 (74.55)
T3 12 (21.82)
T4 2 (3.64)
Gleason scores
7 27 (48.21)
8 5 (9.09)
9 19 (33.93)
10 4 (7.14)
PSA levels on establishing the diagnosis (ng/ml)
10 > x > 5 13 (23.21)
20 > x ≥ 10 9 (16.36)
≥ 20 33 (58.93)
Endocrine treatment 49 (89.09)
Table 2 Volumes of the delineated structures and rectal diameters in
prone and supine positions
Structure Position Mean volume
(cm3)
Standard
deviation (SD)
p
value
GTVp Prone 130.11 49.13 0.217
Supine 133.28 50.87
PVS Prone 188.77 58.19 0.748
Supine 190.23 58.20
PTV Prone 1123.54 138.90 0.282
Supine 1130.98 146.66
Whole rectum
(R)
Prone 155.13 105.26 <0.001
Supine 95.61 45.89
Rectal
subsegment
R1
Prone 50.32 31.84 <0.001
Supine 34.76 23.64
Rectal
subsegment
R2
Prone 74.37 41.51 <0.001
Supine 50.78 27.64
Colon Prone 580.32 299.38 0.486
Supine 604.37 337.12
Small bowel Prone 812.93 354.25 0.373
Supine 772.71 353.21
Urinary bladder Prone 184.18 117.13 0.403
Supine 192.40 112.56
Rectal diameter Position Mean diameter
(mm)
Standard error
(SE)
p value
AP Prone 50.60 2.20 <0.001
Supine 36.70 1.50
Lateral Prone 43.80 2.60 0.003
Supine 35.90 1.80
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limiting organs, tolerating a 50–60 Gy dose at conventional
fractionation [17, 18]. Normal tissue complication probability
(NTCP) studies suggest that the small intestine volume receiv-
ing 15 and 45 Gy (V15 and V45) is a relevant parameter for GI
morbidity [19, 20]. According to the review of Fiorino et al.
[21], keeping V70 and V75 to <25 and 5%, respectively, results
in a decrease in the development of late rectal bleeding.
Moderate dose volumes, such as V40 and V50 are predictive
for chronic late incontinence [22] and are also important in
developing rectal bleeding [21]. The dosimetric analysis [23]
of the anatomical subregions showed that rectal bleeding is
associated with V70 of the anorectal region, fecal inconti-
nence with V15 of external sphincter, and V55 of the
iliococcygeal muscle, whereas stool frequency with V40 of
the levator ani and V45 of the iliococcygeal muscle. In the
prospective study of Dréan et al. [24], rectal subregions at risk
have been delineated, and the authors have found that the
exposure of the subprostatic anterior hemirectum and the up-
per part of the anal canal was 4 Gy higher in patients devel-
oping rectal bleeding.
Table 3 Rectum–prostate distance and intraobserver and interobserver variability correlation in prone and supine positions
Distance Position Mean (mm) Standard error
(SE)
p value Intraobserver variability – Correlation coefficient (r) Interobserver variability –
Correlation coefficient (r)
Examiner 1 Examiner 2
Left lateral Prone 6.50 0.40 0.062 0.92 0.90 0.89
Supine 5.70 0.40
Mediosagittal Prone 2.80 0.30 0.026 0.86 0.89 0.95
Supine 2.20 0.30
Right lateral Prone 5.90 0.40 0.173 0.80 0.74 0.78
Supine 5.40 0.40
Table 4 Small intestine and colon exposure in prone and supine
position
Organ at
risk
DVH
parameter
Position Mean
volume
(cm3)
Standard
deviation (SD)
p
value
Small
intestine
V20 Gy Prone 79.85 89.83 <0.001
Supine 170.34 103.62
V30 Gy Prone 36.74 51.24 <0.001
Supine 84.55 63.01
V40 Gy Prone 16.99 26.08 <0.001
Supine 32.91 31.35
V50Gy Prone 0.16 1.06 0.398
Supine 0.33 1.54
Colon V20 Gy Prone 122.43 74.52 <0.001
Supine 181.22 109.48
V30 Gy Prone 84.09 57.17 <0.001
Supine 121.21 73.36
V40 Gy Prone 53.23 44.20 0.043
Supine 63.19 44.89
V50 Gy Prone 2.06 4.02 0.627
Supine 1.81 3.62
Table 5 Exposure of rectal segments and urinary bladder in prone and
supine positions
Organ at risk DVH
parameter
Position Mean
relative
volume
(%)
Standard
deviation
(SD)
p
value
Whole rectum V30Gy Prone 106.40 118.98 0.296
Supine 89.60 7.46
V40Gy Prone 65.79 14.96 <0.001
Supine 78.58 10.14
V50Gy Prone 35.51 13.83 <0.001
Supine 48.38 12.29
V60Gy Prone 17.45 8.18 <0.001
Supine 24.04 9.11
V70Gy Prone 7.57 4.10 <0.001
Supine 10.43 4.97
V75Gy Prone 3.67 2.61 0.021
Supine 4.58 3.19
Rectal
subsegment
R1
V30 Gy Prone 99.78 0.75 0.735
Supine 99.80 0.61
V40Gy Prone 80.58 13.50 <0.001
Supine 94.95 5.74
V50Gy Prone 52.25 14.18 <0.001
Supine 68.55 10.90
V60Gy Prone 32.37 10.90 <0.001
Supine 40.49 10.13
V70Gy Prone 16.51 5.83 <0.001
Supine 20.74 7.14
V75Gy Prone 8.79 4.52 0.099
Supine 9.97 5.67
Rectal
subsegment
R2
V30Gy Prone 99.52 1.21 0.001
Supine 98.61 1.96
V40Gy Prone 78.55 12.66 <0.001
Supine 91.45 6.05
V50Gy Prone 49.40 13.14 <0.001
Supine 64.83 9.89
V60Gy Prone 28.95 9.04 <0.001
Supine 37.43 8.76
V70Gy Prone 13.52 4.75 <0.001
Supine 17.86 5.79
V75Gy Prone 6.82 3.59 0.051
Supine 7.86 4.43
Bladder V30Gy Prone 95.82 7.10 0.657
Supine 95.45 5.13
V40Gy Prone 67.99 18.89 0.687
Supine 68.78 16.13
V50Gy Prone 41.90 16.53 0.982
Supine 41.86 14.84
V60Gy Prone 26.73 11.77 0.235
Supine 25.36 10.62
V70Gy Prone 15.91 7.90 0.276
Supine 14.94 7.31
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Technological advances allowing rectal sparing include
endorectal balloons filled with air or water, reducing the expo-
sure of the posterior rectal wall by moving away the prostate
from it, depending on the volume of the balloons [25].
Bioabsorbable tissue spacers injected into the retroprostatic
fascia also increase the distance between the prostate and the
anterior rectal wall, resulting in significant reduction in both
acute and late GI toxicities [26]. Regarding patient positioning,
Zelefsky et al. [27] and McLaughlin et al. [28] have described
significantly lower rectal doses in prone position, using
3DCRT technique. The results have also been confirmed in
the phase II trial of O’Neil et al. [29] and by Bajon et al. using
tomotherapy [30]. Nevertheless, Baylay et al. [31] have found
supine position more favorable by using larger PTVmargins in
prone position, andKato et al. [32] by applying IMRT in supine
and 3DCRT in prone position. In prone position, the decreased
rectal exposure is a result of the posterior retraction of the
rectum and anterior displacement of the prostate; however,
the accurate mechanism of it is unknown [27, 28, 32].
In the 3D-CRT of rectal malignancies, a prone treatment
position without a belly board compared to a supine posture
results in the reduction of the irradiated small intestine volume
[33]. In case of pelvic malignancies, a larger decrease in the
small intestine exposure can be obtained by the additional use
of a belly board in comparison with both prone position alone
[34, 35] or supine position [36, 37]. The use of IMRT tech-
nique decreases bowel doses by 40–50%, as compared to 3D-
CRT [38, 39]. In case of gynecological and rectal tumors, a
belly board assisted prone position using IMRT results in a
further reduction in the irradiated volume of the small intes-
tine, even in low dose areas [40, 41]. The advantage of the use
of a belly board is also confirmed in postoperatively irradiated
patients [42, 43], which might be the consequence of the sig-
nificantly higher mobilization of the small intestine loops. The
findings of Fu et al. [44] show that the gain of the use of a
belly board is greater if the irradiated small intestine volume
close to the target volume is larger. According to that study, a
prone position on a belly board results in a remarkable de-
crease in the small bowel volume in case of gynecological
malignancies but not in rectal cancer patients. A full bladder
also functions as a natural spacer, transposing the small intes-
tine loops from the pelvis to the abdomen, resulting in a re-
duction in the irradiated small intestine volume [42].
In rectal cancer patients treated with chemo-radiotherapy,
Baglan et al. [19] have demonstrated an explicit relationship
between the volume of the small bowel receiving at least
15 Gy and the degree of acute small intestinal toxicity.
Robertson et al. [45] have proved that a reduction in the small
bowel volume receiving low dose results in a significant de-
crease in the complication rate. Both authors have delineated
the single small intestinal loops. In case of gynecological can-
cer patients treated with pelvic IMRT, Roeske et al. [20] have
detected that drawing the abdominal space, the risk of acute
GI toxicity is five times as little for small bowel volume of
100 cm3 gaining the prescribed 45 Gy dose as of 200 cm3.
According to Gunnlaugsson et al. [46], the former technique is
the recommended contouring method instead of delineating
the abdominal space. Gunnlaugsson et al. have observed
strong correlation between the occurrence of early side effects
and small intestinal loop exposure, and no significant connec-
tion with the peritoneal cavity.
Our study was limited by the lack of delineating the penile
bulb, and the relatively small number of patients involved,
which however was double the number of patients previously
reported. As most papers have described larger intrafraction
prostate and respiratory motion in prone position [11] and lit-
erature data [47] show that a 3 mm PTV margin allows for
CTV to be covered for 99% of cases when daily CBCT is used,
accurate patient repositioning, daily reconstruction of the rec-
tum, prostate safety margins, early toxicity and life quality dur-
ing and after RTwere also evaluated, and found to be similar to
literature data of patients treated in supine position. These
promising results have recently been submitted. Late toxicities
need further examination due to the short follow-up period.
In conclusion, in the pelvic IMRT for prostate cancer, a
prone position on a belly board decreases the irradiated small
bowel volumes even in low dose ranges and contributes to
rectal sparing. The relative dose reduction in the rectal exposure
might be a consequence of the slight departure between the
prostate wall and the rectal wall, as consistent with the litera-
ture, and the increasing volume and diameters of the rectum
generated by the displacement of rectal gases. Considering the
dosimetric advantages, prone position on a belly board could
be recommended for the pelvic IMRT of prostate cancer.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
Ethical Approval All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institu-
tional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
The study was registered on September 19, 2016 by the Human
Investigation Review Board, Regional Human Biomedical Research
Ethics Committee, Albert Szent-Györgyi Health Centre, University of
Szeged, Hungary, registration number: WHO 3856/2016.
Informed Consent Informed consent was obtained from all individual
participants included in the study.
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM
(2010) Estimates of worldwide burden of cancer in 2008:
Globocan 2008. Int J Cancer 127:2893–2917
R. Kószó et al.
2. Juloori A, Shah C, Stephans K, Vassil A, Tendulkar R (2016)
Evolving paradigm of radiotherapy for high-risk prostate cancer:
current consensus and continuing controversies. Prostate Cancer
2016:2420786
3. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L,
Canadian GU Radiation Oncologist Group (2001) Controversies in
prostate cancer radiotherapy: consensus development. Canadian
GU Radiation Oncologist Group. Can J Urol 8:1314–1322
4. Andreyev HJ (2007) Gastrointestinal problems after pelvic radio-
therapy: the past, the present and the future. Clin Oncol (R Coll
Radiol) 19:790–799
5. Stacey R, Green JT (2014) Radiation-induced small bowel disease:
latest developments and clinical guidance. Ther Adv Chronic Dis 5:
15–29
6. Theis V, Sripadam R, Ramani V, Lal S (2010) Chronic radiation
enteritis. Clin Oncol 22:70–83
7. Kennedy G, Heise C (2005) Radiation colitis and proctitis. Clin
Colon Rectal Surg 20:64–72
8. Olopade F, Norman A, Blake P, Dearnaley DP, Harrington KJ,
Khoo Vet al (2005) A modified inflammatory bowel disease ques-
tionnaire and the Vaizey incontinence questionnaire are simple
ways to identify patients with significant gastrointestinal symptoms
after pelvic radiotherapy. Br J Cancer 92:1663–1670
9. Wiesendanger-Wittmer E, Sijtsema N, Muijs C, Beukema JC
(2012) Systematic review of the role of a belly board device in
radiotherapy delivery in patients with pelvic malignancies.
Radiother Oncol 102:325–334
10. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A et
al (1999) Long term tolerance of high dose three-dimensional con-
formal radiotherapy in patients with localized prostate carcinoma.
Cancer 85:2460–2468
11. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classifi-
cation of malignant tumors, 7th edn. Wiley-Blackwell, London
12. Mellinger GT, Gleason D, Bailar J 3rd (1967) The histology and
prognosis of prostatic cancer. J Urol 97:331–337
13. Lawton CAF,Michalski J, El-Naga I, Buyyounouski MK, LeeWR,
Menard C et al (2009) RTOG GU radiation oncology specialists
reach consensus on pelvic lymph node volumes for high-risk pros-
tate cancer. Int J Radiat Oncol Biol Phys 74:383–387
14. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU
(2010) Radiation dose-volume effects of the urinary bladder. Int J
Radiat Oncol Biol Phys 76(Suppl 3):S116–S122
15. Gami B, Harrington K, Blake P, Dearnaley D, Tait D, Davies J,
Norman AR, Andreyev HJN (2003) How patients manage gastro-
intestinal symptoms after pelvic radiotherapy. Aliment Pharmacol
Therapeut 18:987–994
16. Andreyev H (2007) Gastrointestinal symptoms after pelvic radio-
therapy: a new understanding to improve management of symptom-
atic patients. Lancet Oncol 8:1007–1017
17. Letschert JGJ (1995) The prevention of radiation-induced small
bowel complications. Eur J Cancer 31:1361–1365
18. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO (2010)
Radiation dose-volume effects in radiation-induced rectal injury.
Int J Radiat Oncol Biol Phys 76(Suppl 3):S123–S129
19. Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA,
Robertson JM (2002) The dose–volume relationship of acute small
bowel toxicity from concurrent 5-FU-based chemotherapy and ra-
diation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 52:
176–183
20. Roeske JC, Bonta D, Mell LK, Lujan AE, Mundt AJ (2003) A
dosimetric analysis of acute gastrointestinal toxicity in women re-
ceiving intensity-modulated whole-pelvic radiation therapy.
Radiother Oncol 69:201–207
21. Fiorino C, Valdagni R, Rancati T, Sanguineti G (2009) Dose-
volume effects for normal tissues in external radiotherapy: pelvis.
Radiother Oncol 93:153–167
22. Peeters ST, Hoogeman MS, Heemsbergen WD, Hart AA, Koper
PC, Lebesque JV (2006) Rectal bleeding, fecal incontinence, and
high stool frequency after conformal radiotherapy for prostate can-
cer: normal tissue complication probability modeling. Int J Radiat
Oncol Biol Phys 66:11–19
23. SchaakeW, van der Schaaf A, van Dijk LV, Bongaerts AH, van den
Bergh AC, Langendijk JA (2016) Normal tissue complication prob-
ability (NTCP) models for late rectal bleeding, stool frequency and
fecal incontinence after radiotherapy in prostate cancer patients.
Radiother Oncol 119:381–387
24. Dréan G, Acosta O, Ospina JD, Fargeas A, Lafond C, Corrégé G et
al (2016) Identification of a rectal subregion highly predictive of
rectal bleeding in prostate cancer IMRT. Radiother Oncol 119:388–
397
25. van Lin EN, Hoffmann AL, van Kollenburg P, Leer JW, Visser AG
(2005) Rectal wall sparing effect of three different endorectal bal-
loons in 3D conformal and IMRT prostate radiotherapy. Int J Radiat
Oncol Biol Phys 63:565–576
26. Serrano N, Kalman NS, Anscher MS (2017) Reducing rectal injury
in men receiving prostate cancer radiation therapy: current perspec-
tives. Cancer Manag Res 9:339–350
27. Zelefsky MJ, Happersett L, Leibel SA, Burman CM, Schwartz L,
Dicker AP et al (1997) The effect of treatment positioning on nor-
mal tissue dose in patients with prostate cancer treated with three-
dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys
37:13–19
28. McLaughlin PW, Wygoda A, Sahijdak W, Sandler HM, Marsh L,
Roberson P et al (1999) The effect of patient position and treatment
technique in conformal treatment of prostate cancer. Int J Radiat
Oncol Biol Phys 45:407–413
29. O’Neil L, Armstrong J, Buckney S, Assiri M, Cannon M,
Holmberg O (2008) A phase II trial for the optimisation of treat-
ment position in the radiation therapy of prostate cancer. Radiother
Oncol 88:61–66
30. Bajon T, Piotrowski T, Antczak A, Bąk B, Błasiak B, Kaźmierskaa
J (2011) Comparison of dose-volume histograms for supine and
prone position in patients irradiated for prostate cancer – a prelim-
inary study. Rep Pract Oncol Radiother 16:65–70
31. Bayley AJ, Catton CN, Haycocks T, Kelly V, Alasti H, Bristow R et
al (2003) A randomized trial of supine vs. prone positioning in
patients undergoing escalated dose conformal radiotherapy for
prostate cancer. Radiother Oncol 70:37–44
32. Kato T, Obata Y, Kadoya N, Fuwa N (2009) A comparison of prone
three-dimensional conformal radiotherapy with supine intensity-
modulated radiotherapy for prostate cancer: which technique is
more effective for rectal sparing? Br J Radiol 82:654–661
33. Drzymala M, HawkinsMA, Henrys AJ, Bedford J, Norman A, Tait
DM (2009) The effect of treatment position, prone or supine, on
dose–volume histograms for pelvic radiotherapy in patients with
rectal cancer. Br J Radiol 82:321–327
34. Kim TH, Chie EK, Kim DY, Park SY, Cho KH, Jung KH et al
(2005) Comparison of the belly board device method and the
distended bladder method for reducing irradiated small bowel vol-
umes in preoperative radiotherapy of rectal cancer patients. Int J
Radiat Oncol Biol Phys 62:769–775
35. Huh SJ, Park W, Ju SG, Lee JE, Han Y (2004) Small-bowel dis-
placement system for the sparing of small bowel in three-
dimensional conformal radiotherapy for cervical cancer. Clin
Oncol 16:467–473
36. Martin J, Fitzpatrick K, Horan G, McCloy R, Buckney S, O'Neill L
et al (2005) Treatment with a belly-board device significantly re-
duces the volume of small bowel irradiated and results in low acute
toxicity in adjuvant radiotherapy for gynecologic cancer: results of
a prospective study. Radiother Oncol 74:267–274
37. Pinkawa M, Gagel B, Demirel C, Schmachtenberg A, Asadpour B,
Eble MJ (2003) Dose–volume histogram evaluation of prone and
Prone Positioning on a Belly Board Decreases Rectal and Bowel Doses in Pelvic Intensity-Modulated Radiation...
supine patient position in external beam radiotherapy for cervical
and endometrial cancer. Radiother Oncol 69:99–105
38. Mundt A, Roeske J, Lujan A (2002) Intensity-modulated radiation
therapy in gynecologic malignancies. Med Dosimetry 27:131–136
39. Portelance L, Chao K, Grigsby P, Bennet H, Low D (2001)
Intensity-modulated radiation therapy (IMRT) reduces small bow-
el, rectum, and bladder doses in patients with cervical cancer re-
ceiving pelvic and Para-aortic irradiation. Int J Radiat Oncol Biol
Phys 51:261–266
40. Stromberger C, Kom Y, Kawgan-Kagan M, Mensing T, Jahn U,
Schneider A et al (2010) Intensity-modulated radiotherapy in pa-
tients with cervical cancer. An intra-individual comparison of prone
and supine positioning. Radiat Oncol 5:63–68
41. Beriwal S, Jain SK, Heron DE, de Andrade RS, Lin CJ, Kim H
(2007) Dosimetric and toxicity comparison between prone and su-
pine position IMRT for endometrial cancer. Int J Radiat Oncol Biol
Phys 67:485–489
42. Kim TH, Kim DY, Cho KH, Kim YH, Jung KH, Ahn JB et al
(2005) Comparative analysis of the effects of belly board and blad-
der distension in postoperative radiotherapy of rectal cancer pa-
tients. Strahlenther Onkol 181(9):601–605
43. Saynak M, Kucucuk S, Aslay I (2008) Abdominal pillow for
the sparing of small bowel in four-field conventional pelvic
radiotherapy. Eur J Gynaecol Oncol 29:643–648
44. Fu YT, Lam JC, Tze JM (1995) Measurement of irradiated small
bowel volume in pelvic irradiation and the effect of a belly board.
Clin Oncol (R Coll Radiol) 7:188–192
45. Robertson JM, Lockman D, Yan D, Wallace M (2008) The
dose-volume relationship of small bowel irradiation and
acute grade 3 diarrhea during chemoradiotherapy for rectal
cancer. Int J Radiat Oncol Biol Phys 70:413–418
46. Gunnlaugsson A, Kjellen E, Nilsson P, Bendahl PO, Willner
J, Johnsson A (2007) Dose–volume relationships between
enteritis and irradiated bowel volumes during 5-fluorouracil
and oxaliplatin based chemoradiotherapy in locally advanced
rectal cancer. Acta Oncol 46:937–944
47. Gill SK, Reddy K, Campbell N, Chen C, Pearson D (2015)
Determination of optimal PTV margin for patients receiving
CBCT-guided prostate IMRT: comparative analysis based on
CBCT dose calculation with four different margins. J Appl
Clin Med Phys 16:252–262
R. Kószó et al.
  
II. 
  
Breast radiotherapy
A simple clinical method for predicting the benefit of prone vs. supine
positioning in reducing heart exposure during left breast radiotherapy
Zsuzsanna Kahán a,⇑, Ferenc Rárosi b, Szilvia Gaál a, Adrienn Cserháti a, Krisztina Boda b, Barbara Darázs a,
Renáta Kószó a, Ferenc Lakosi c,d, Ákos Gulybán c,e, Philippe A. Coucke c, Zoltán Varga a
aDepartment of Oncotherapy; bDepartment of Medical Informatics, University of Szeged, Hungary; cDepartment of Radiation Oncology, University Hospital of Liège, Belgium;
d Institute of Diagnostic Imaging and Radiation Oncology, Health Center, Kaposvár University, Hungary; eRadiation Oncology Department, Europe Hospitals Brussels, Belgium
a r t i c l e i n f o
Article history:
Received 26 April 2017
Received in revised form 20 December 2017
Accepted 22 December 2017
Available online 17 January 2018
Keywords:
Breast radiotherapy
Clinical tool
Heart protection
Individual positioning
LAD protection
a b s t r a c t
Background and purpose: The benefit of reduced radiation heart exposure in the prone vs. supine position
individually differs. In this prospective cohort study, the goal was to develop a simple method for the
operation of a validated model for the prediction of preferable treatment position during left breast
radiotherapy.
Material and methods: In 100 cases, a single CT slice was utilized for the collection of the needed patient-
specific data (in addition to body mass index, the distance of the LAD from the chest wall and the area of
the heart included in the radiation fields at the middle of the heart in the supine position). Outcome was
analyzed in relation to the full CT series acquired in both positions and dosimetric data.
Results: Great consistency was found between the tested and original method regarding sensitivity and
specificity. The prioritization of LAD dose, and the use of heart dose and position-specific dose constraints
as safety measures ensure sensitivity and specificity values of 82.8% and 87.3%, respectively. In an addi-
tional ‘‘routine clinical practice” series of 60 patients the new method seemed feasible in routine clinical
practice. External testing on a 28-case series indicated similar accuracy.
Conclusion: We consider this simple clinical tool appropriate for assisting individual positioning aiming
at maximum heart protection during left breast irradiation.
 2018 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 126 (2018) 487–492
Radiotherapy is an essential component of the management of
early breast cancer. The outcome in most cases is favorable, the
majority of the affected patients become long survivors. Breast
radiotherapy, however, may increase the risk of non-breast
cancer-related morbidities, among which heart diseases rank the
first [1,2]. Radiation-induced heart damage clearly depends on
the dose exposed to its different structures (3,4). While older radio-
therapy practices caused more significant late hazards, heightened
awareness and the use of current technical developments make
this danger much lower [1,4,5]. Although the application of mod-
ern radiotherapy planning and delivery significantly improves
the control of radiation dose, in many cases a part of the heart,
and especially the left anterior descending artery (LAD) located
to its anterior surface still receive a dose sufficient to cause long-
term adverse effects. Radiogenic diffuse myocardium damage
including microvasculature abnormalities, degenerative cardiomy-
ocyte and interstitial fibrotic changes may be controlled if not
extensive, but the damage of the macrovasculature indistinguish-
able from coronary arteriosclerosis due to other causes more likely
lead to a fatal outcome [3,6–8]. The exposure of the heart and the
LAD are related [9–11], and irradiation-related cardiac morbidity
and mortality are considered to be consequences of late manifest-
ing coronary artery damage. Hence the verification and control of
the dose to the LAD, is of prime importance [8,9,11,12].
With the aim of cardiac dose sparing and avoidance, numerous
newmethods have been developed [4,5]. These include the breath-
holding techniques, prone positioning (both operate by separating
the heart and the radiation fields), IMRT, proton irradiation or the
reduction in the volume to be irradiated, partial breast irradiation
(PBI). A significant increase in the number of clinical studies
[11–20], and a recent survey on clinical practice [21] suggest that
prone positioning has become an alternative of conventional
supine positioning in some centers. Prone positioning always pro-
vides dramatic reduction in the ipsilateral lung dose, and in many
cases significantly reduces heart exposure, too. A potential
disadvantage is inferior repositioning accuracy, which may be
improved with experience [18] or may be compensated by online
daily correction [12,22].
https://doi.org/10.1016/j.radonc.2017.12.021
0167-8140/ 2018 Elsevier B.V. All rights reserved.
⇑ Corresponding author at: Department of Oncotherapy, University of Szeged,
Korányi fasor 12, H-6720 Szeged, Hungary.
E-mail address: kahan.zsuzsanna@med.u-szeged.hu (Z. Kahán).
Radiotherapy and Oncology 126 (2018) 487–492
Contents lists available at ScienceDirect
Radiotherapy and Oncology
journal homepage: www.thegreenjournal .com
Prone positioning was first invented for the irradiation of large-
breasted women [23,24]. Indeed, since gravity pulls the breast
away from the chest wall, the geometry of a pendulous breast
and the tangential irradiation fields gets advantageous in the prone
position [12]. Taking the overall population of breast cancer
patients, however, prone positioning has such effect in 77–87% of
cases only [11,14,15,19]. As a consequence, the position-
dependent dose to the LAD or heart also individually differs
[11,19,20]. Different approaches exist for selecting the optimal
position in left breast cancer cases. Kirby et al. found that a PTV
> 1000 cm3 favors prone positioning [11]. Zhao et al. developed a
two-step decision-analysis algorithm that, based on the anatomi-
cal features detected on a prone CT series, classified patients to
prone radiotherapy or to a second CT in the supine position for
comparison [25]. We have demonstrated that a statistical model
utilizing 3 anatomical determinants (the body mass index [BMI],
the distance of the LAD from the chest wall and the area of the
heart included in the radiation fields at the middle of the heart
in the supine position) of the patient gives accurate estimates on
the benefit of one specific position over the other by means of
LAD or heart doses [19]. Here we report on an original method
for providing the necessary patient-specific data based on a single
CT slice image representing the middle of the heart. In this
prospective study, following the validation of the clinical tool, also
its routine use has been tested on a separate series of cases.
Patients and methods
The study was approved by the Institutional Review Board of
the University of Szeged, and all the enrolled patients gave their
written informed consent to participation. Eligible patients needed
postoperative left breast radiotherapy.
Outline of the study
First, a single CT slice image at the middle of the heart (refer-
ence plane, Pref) was acquired with the help of an AP scout view
in the supine position (Fig. 1A). On that CT scan, the shortest dis-
tance between the anterior surface of the LAD and the chest wall
(Dmed) and the area of the heart (Aheart) included in the radiation
fields were measured after placing a straight line between the bor-
der of the ipsilateral latissimus dorsi muscle and the lateral edge of
the sternum (Fig. 1B); these data (representing the topography of
the heart) were introduced to the calculator together with the
patient’s BMI (which correlated with the volumes of the breast
and heart) as previously described in detail [19]. The calculator
based on a validated statistical model provided the estimated
LAD and heart dose differences in the prone vs. supine position
of the individual patient. In the first validation set of 100 patients,
CT series were acquired in both the supine position and prone posi-
tion. Conformal radiation treatment plans were generated in both
positions using conventional 6 MV tangential photon fields set up
isocentrically and median 2 (1–3) individually weighted 6/15 MV
segmental fields superimposed on the tangential fields using a
multileaf collimator as described [18,19]. Wedges were used in
almost all supine radiation plans. A mean dose to the PTV of 50
Gy (25 fractions) and a uniform distribution (5% + 7%) of the pre-
scribed dose to 95% of the PTV, were aimed at. The consistency of
all contouring activities had been ensured by a chief radiation
oncologist (ZK) and an experienced radiologist (AC) [26]. Equiva-
lent heart and LAD volume contouring in either setup was ensured
by one author (ZK). In the next ‘‘routine clinical practice” set of 60
patients, the acquisition of a single series of CT images according to
the suggestion of the calculator was aimed at, and a second CT ser-
ies was taken only if any of the dose constraints approved for the
specific position were not reached in the position suggested by
the calculator. In this series of patients’ dose constraints were spec-
ified on the basis of previously recorded data. The upper range lim-
its of the 90% percentile of dosimetry data in the preferred position
were the following: mean LAD dose [MDLAD]: 12.9 Gy and 12.5 Gy,
V25Gyheart: 2.4% and 4.7%, in the prone position and supine position,
respectively. In true discordant cases, our strategy for selecting
treatment position was to consider the LAD dose as a primary deci-
sive factor.
In the validation set, data on LAD and heart dose differences
between the two treatment positions were extracted from the
planning system and estimated by the calculator, whereas in the
‘‘routine clinical practice” series only the estimated dose
differences were available. Analyses were performed on 1. the
equivalence of the Pref with the median plane of the full series of
CT scans acquired in the supine position (Pmed) and 2. the effect
of plane miss on the patient-related determinants and choice of
preferable position. The sensitivity and specificity of this simple
clinical method were evaluated based on the dosimetry data
obtained using the topogram for selecting the position (n = 100).
In the ‘‘routine clinical practice” series, the acceptability of the
position as predicted by the calculator, the LAD and heart doses
achieved without taking 2 CT series, and the need of performing
a second CT series and changing position or irradiation technique
were analyzed.
External testing
The supine and prone CT series and supine topogram of patients
included in the study ‘‘Individualized positioning for maximum
heart and index breast protection during breast irradiation: com-
parative study between Prone and Supine (Approval: 26/09/2013,
B707201318246) were retrospectively used for independent test-
ing. The protocol of patient positioning, delineation and radiation
treatment planning has been described [27].
First, Pref was selected on the topogram. Then, the predictors
BMI, Dmed, Aheart as measured in Pref were introduced to the calcu-
lator. As a second step, Dmed, Aheart were also measured in Pmed. LAD
and heart dose differences between the two treatment positions
extracted from the planning system and estimated by the calcula-
tor were analyzed. Finally, the correctness of Pref was evaluated.
Statistical methods
The calculator had been developed based on linear regression
models utilizing the patients’ anatomical features, with DMDLAD
and DV25Gyheart as dependent variables [19]. With a single cut-off
point, a case was classified to prone positioning when the pre-
dicted value exceeded that value. Thresholds were optimized
based on sensitivity and specificity as calculated from previous
Fig. 1. The simple clinical tool generates patient-specific data to predict the benefit
of prone positioning. After selecting the reference plane (Pref) at the middle of the
heart on the AP scout view (A), a single CT slice is acquired for the measurement of
those determinants (Dmed and Aheart) (B) which operate the calculator to provide
estimates of the doses to the LAD or heart.
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[19] and present data (Table 1). Sensitivity and specificity were cal-
culated with supine positioning as positive determinant in the
model. For DMDLAD a threshold of 0.6 Gy, and for DV25Gyheart a
cut-off point of 1.0% were chosen. In the definition of the cut-off
points, a sensitivity of 80% at the minimum and the maximum
achievable value of specificity was required.
LAD and heart dose constraints achievable by selecting the
preferable position were specified by percentage estimation. Sta-
tistical analysis was performed with SPSS 22.0 for Windows.
Results
Validation set
In 55/100 cases, Pref was the same as Pmed while in 28 and 17
cases, Pref and Pmed differed by 1 or more planes, respectively. More
among the incorrectly defined Pref cases were shifted toward the
caudal than the cranial direction. This resulted in smaller mean
Dmed and larger mean Aheart values among the plane miss cases
overall (Table 2). Within the whole series, no change in the fre-
quency of plane misses could be detected by time. Incongruency
among DMDLAD and DV25Gyheart in the supine and prone position
as predicted by the calculator on the basis of Pref vs. Pmed data,
was present in 14 and 18 of the cases, respectively; these were
all of small numerical values (Fig. 2A, B). When the LAD and heart
dose differences predicted by the calculator based on the Pref val-
ues were compared with the original dosimetric data from plans
generated in both positions, the suggestion proved invalid in 14
(MDLAD) and 16 (V25Gyheart) cases (Fig. 2C, D). We have compared
the sensitivity and specificity of DMDLAD and DV25Gyheart provided
by the simple method based on a single CT scan with that of the
original method that indicated high consistency [19] (Table 1).
Based on these findings, the cut-off values of 0.6 Gy (DMDLAD)
and 1.0% (DV25Gyheart) have been selected for further analyses and
practice.
Next, the concordance of calculator-predicted treatment posi-
tion based on DMDLAD vs. DV25Gyheart and the need for intervention
were analyzed in the validation set. In 28 supine-predicted cases
and 64 prone-predicted cases, the same treatment position was
suggested by both measures (Table 3). Among the 28 supine-
predicted cases in 2, the radiotherapy plan revealed that MDLAD
> 12.5 Gy, but only 1 could be improved by changing the treatment
position. Among the 64 prone-predicted cases in 8, the MDLAD
exceeded the dose constraint of 12.9 Gy; only 3 plans could be
improved by applying the supine position. Among the discordant
cases, DMDLAD suggested prone position in 3 and supine position
in 5 cases; in both groups in a single case each could the LAD dose
be improved by changing the treatment position. In altogether 7
cases, a different intervention (IMRT) had to be applied (Table 3).
‘‘Routine clinical practice” set
In the ‘‘routine clinical practice” series of 60 patients, the new
method proved feasible. All patients received treatment in the
position suggested by the calculator except one, who had to receive
a second CT in the other position due to unacceptable LAD dose.
The other patients had MDLAD and V25Gyheart values well below
the predefined dose limits, and these were similar to the values
calculated in the validation set (Table 4).
External testing
In a series of 28 breast cancer patients from Liege, the predictors
BMI, Dmed and Aheart significantly differed from the same parame-
ters among the patients from Szeged. In 18/28 cases, Pref was equal
or close to Pmed (6 mm), while in 10, cases Pref varied from Pmed by
9–16 mm. Comparing the calculator-provided dose differences
with the treatment planning data, favored treatment position
was correct in 24/28 (accuracy: 85.7%) and 23/28 (accuracy:
82.1%) cases taking into account the LAD and heart doses,
Table 1
Classification measures for DMDLAD and DV25Gyheart using a single discrimination threshold. Great consistency is seen between the original cohort [19] and the present series.
Original method (double CT method, n = 83) Simple tool (single CT method, n = 100)
Cut-off point Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
DMDLAD (Gy) 0.6 66.6 91.1 72.4 91.5
0.3 70.8 90.7 75.9 91.5
0 74.4 90.0 75.9 91.5
0.3 77.7 88.9 79.3 88.7
0.6 80.7 87.5 82.8 87.3
0.9 83.4 86.0 82.8 83.1
1.2 85.4 83.6 86.2 81.7
1.5 86.5 81.7 86.2 77.5
1.8 86.8 79.9 93.1 76.1
DV25Gyheart (%) 0 47.9 89.7 50 90.8
0.25 56.2 88.8 58.3 89.5
0.50 63.2 85.9 64 88
0.75 72.4 82.4 68 85.3
1 78.8 77.7 80 85.3
1.25 84.0 74.0 84 81.3
1.50 87.4 77.0 92 78.6
1.75 89.9 62.1 96 74.6
Table 2
Dmed and Aheart values (mean ± SD) as measured on Pref vs. Pmed in all cases or in correctly and incorrectly specified Pref cases; the measurements were performed on 2 CT scans at
the middle of the heart either identified with the help of an A-P scout view (Pref) or selected from a full CT series (Pmed).
All cases (n = 100) Correct plane (n = 55) Plane miss (n = 45)
Pref Pmed Pref Pmed Pref Pmed
Dmedian (cm) 1.27 ± 0.59 1.25 ± 0.67 1.35 ± 0.55 1.17 ± 0.63 1.18 ± 0.63 1.34 ± 0.71
Aheart (mm2) 768.8 ± 487.4 671.6 ± 450.1 730.7 ± 537.4 721.5 ± 511.2 815.4 ± 419.5 610.5 ± 358.1
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respectively. Sensitivity and specificity of DMDLAD was 83.3% and
86.4%, respectively, whereas sensitivity and specificity of
DV25Gyheart was 100.0% and 80.0%, respectively.
Discussion
According to the present study and others [11,14,15,19,20], in
about 20% of the cases, prone positioning during left breast radio-
therapy increases the dose to the LAD or the heart. To estimate and
select the preferable positioning mode, supine CT seems the best
approach to consider the patient’s anatomical determinants. We
have shown that a single CT scan at the middle of the heart may
replace a whole CT series by providing consistent anatomical data
thus avoiding extra radiation exposure to the patient and work
load to the staff. Based on the outcome of the external implemen-
tation of the method on an independent case series, we recom-
mend its use after local testing.
Fig. 2. Calculator suggestion of LAD (A) and heart (B) dose differences by the input of Dmed and Aheart based on Pref vs. Pmed; LAD (C) and heart (D) doses according to the
estimation of the simple clinical method based on a single CT scan vs. DVH data extracted from the planning system (n = 100). Dashed lines indicate the cut-off values of 0.6
Gy (DMDLAD) and 1.0% (DV25Gyheart) specified by sensitivity and specificity values.
Table 3
Concordance of treatment position as predicted by DMDLAD vs. DV25Gyheart, in the validation set (n = 100). In concordant cases the suggested position, in discordant cases the
position suggested by DMDLAD was applied unless the dose constraints were exceeded; in such cases the other treatment position or alternative techniques may be tested.
DV25Gyheart
Supine Prone
All MDLAD > 12.5 Gy Change position Other intervention All MDLAD > 12.9 Gy Change position Other intervention
DMDLAD Supine 28 2 1/2 1/2 5 1/5 1/1 –
Prone 3 2/3 1/2 1/2 64 8/64 3/8 5/8
Table 4
LAD and heart doses in the validation set and the ‘‘routine clinical practice” series: in the majority of cases, LAD and heart doses were well below the position-related dose
constraints; for those patients who had higher than accepted doses, an alternative technique had to be applied.
Treatment position n (%) Mean LAD dose (Gy) V25Gyheart (%)
Mean SD Min Max Mean SD Min Max
Validation series Prone 67 (67.0) 6.55 6.03 1.70 26.66 1.16 2.24 0.0 8.75
Supine 33 (33.0) 6.90 3.86 1.71 13.73 1.54 1.38 0.0 4.77
‘‘Routine clinical practice‘‘ series Prone 47 (78.3) 6.58 2.29 1.95 11.24 0.86 0.57 0.1 2.67
Supine 13 (21.7) 7.35 3.05 2.54 15.85 1.15 0.95 0.21 3.57
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Our validated statistical model for predicting the preferable
treatment position utilizes 3 specific measures, and seems the
most complex predictive tool for this purpose in the literature
[19]. In other studies, the in-field heart volume [16,17,25] and
most frequently the size of the breast [4,11] have been used for
selection. An increased BMI has also been related to larger heart
doses [28] or consequential radiation cardiac morbidity [29], but
its role in predicting benefit of prone positioning may be refined
by the use of other patient-related parameters [19]. We consider
the BMI in our calculator as a stable parameter while there is
potential uncertainty in the specification of Pref or imprecision in
the actual measurement of Dmedian or Aheart on a given image. Nev-
ertheless, detailed analysis indicates that accidental imprecision
does not significantly influence final prediction (data not shown).
The dose constraints optimized by individual positioning provides
additional safety in practice. Despite the lack of full equivalence of
the data extracted from the original method vs. the new method,
the ultimate consistency still seems to qualify the developed ‘‘sim-
ple tool” for clinical application.
External use indicated similar accuracy as the originally devel-
oped method. Despite the reassuring results on an independent
series of patients in a radiotherapy center using a slightly different
protocol, the utility of the reported clinical tool could be compro-
mised by the diversity of practice in others. PTV contouring
depends on repositioning accuracy and the method of treatment
verification. Interfractional differences may be especially large in
the prone position [18,30]. Lakosi et al. found population system-
atic error values of 4.5/3.9/3.3 mm in the lateral/longitudinal/verti-
cal directions, while the random error was 5.4/3.8/2.8 mm [27].
Among our recent breast radiotherapy cases, the population sys-
tematic and random error in the lateral/longitudinal/vertical direc-
tions was similar in the prone position vs. supine position
(3.4/2.3/2.7 mm and 7.8/4.6/6.9 mm, respectively vs. 2.2/3.0/1.6
mm and 6.7/5.5/4.5 mm, respectively). Only some groups study
the dose to the coronary arteries [11,12,19,20,31–34]. The outlin-
ing of the coronary vessels shows significant inter-observer varia-
tion that may jeopardize dose verification in the selected position
[35,36]. Different approaches have been tested to improve consis-
tency including the administration of contrast media [35–37]. Lee
et al. developed a new protocol to outline the LAD region which
included 96% of the LAD volume as delineated by 4 experienced
radiation oncologists [37]. Significant impact was made by the
implementation of specific guidelines [35–37]. Since the utility of
the simple tool might be influenced by several factors, in addition
to the use of institutional LAD contouring guidelines and study of
inter-observer variation, we consider essential its testing before
routine use. In the case of hypofractionated radiotherapy, the
model parameters of the calculator should be re-estimated and
the dose constraints should be re-defined.
The benefit of positioning prone vs. supine may be discordant
by means of LAD and heart doses [11,19,34]. We regard the LAD
dose as a surrogate indicator of radiation harm due to its proven
role in late cardiac morbidity [3] and because the LAD being situ-
ated on the anterior surface of the heart is a sensitive marker of
danger if the heart is at all included into radiation. Our strategy
for optimization in individual cases is to consider the MDLAD as pri-
ority that is usually confirmed by the heart dose (as was true for
92% of cases in our series).
The radiation exposure of the heart may be significantly
reduced by the use of respiration-guided techniques including
the deep inspiration breath hold (DIBH) technique and respiratory
gating. In the UK HeartSpare study, supine DIBH provided superior
cardiac sparing than a free-breathing prone position in large-
breasted women [12]. Interestingly, the implementation of DIBH
in the prone position gave the optimal heart sparing results as
compared with that in the supine position or free-breathing [33].
There are some centers that due to resource limitations prioritize
high cardiac dose cases for DIBH [38]. Our tool could be used for
patients either not amenable for or not having access to DIBH
due to patient-specific features (cardiorespiratory problems, lack
of compliance) or limited/no resources, respectively.
We think that since a linear, no-threshold association exists
between the mean heart dose and coronary events [3], doses to
the LAD, right coronary artery or the circumflex artery should be
controlled [20]. Nevertheless, the utilization of heart dose–volume
data only is a possibility if LAD contouring cannot be afforded.
Since good agreement exists between the mean heart dose and
V25Gyheart (Rprone: 0.98, Rsupine: 0.99) or MDLAD (Rprone and Rsu-
pine: 0.87) in both positions (p < 0.001 in all comparisons), here
the presented tool could be adapted to practices which adhere to
the consideration of the mean heart dose.
In summary, we have demonstrated great consistency of our
method based on a validated model for the prediction of treatment
position prone vs. supine with less heart exposure during left
breast radiotherapy; the simplified tool presented here omits the
performance of planning CT in both positions. Based on the results
of its external testing, we truly recommend its use in centers that
apply prone positioning in routine clinical practice. Due to differ-
ences in populations and radiotherapy protocols, local testing is
essential.
Conclusion
We consider this simple clinical tool useful for assisting individ-
ual positioning in routine clinical practice aiming at maximum
heart protection during left breast irradiation.
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Abstract 
Background: Our aim was to implement individualized accelerated partial breast irradiation 
(APBI) based on optimal dose distribution and organ at risk (OAR) protection and identify the 
individually most advantageous technique by considering various tumour- and patient-related 
factors. 
Material and methods: This prospective cohort study included 138 low-risk breast cancer 
patients needing postoperative radiotherapy (RT). APBI plans were generated with 3-
dimensional conformal RT (3D-CRT), sliding window intensity-modulated RT (IMRT) and 
volumetric-modulated arc radiotherapy (VMAT) techniques. If the distance of the centre of the 
planning target volume (PTV) from the body surface was <25 mm, additional plans were 
completed with an electron beam. The prescribed dose to the PTV was 37.5 Gy/10 fractions, 1 
fraction/day. A Plan Quality Index (PQI) adapted for APBI served as a basis for comparisons. 
Results: IMRT plans provided the best homogeneity. Conformity was improved by VMAT the 
most. Mean lung and heart doses were the lowest in 3D-CRT plans. PQI was the most 
favourable in 45 (32.6%) VMAT, 13 (9.4%) IMRT and 9 (6.5%) 3D-CRT plans, while PQIs 
were similar in the rest of the cases. 3D-CRT plans were preferable in patients with large PTV 
volumes. The addition of an electron beam improved the PQI of 3D-CRT plans but had no 
relevant effect on that of IMRT and VMAT. IMRT plans were more often superior than VMAT 
plans if the PTV was superficial (p<0.001), or was situated in the medial (p=0.032) and upper 
quadrants (p=0.046). 
Conclusions: Based on a comprehensive analysis using a PQI adapted for APBI, while IMRT 
and VMAT plans give superior results as compared to 3D-CRT in general, the latter technique 
still may be preferable in a few cases with large PTV. In superficially located tumour beds, the 
addition of an electron beam to 3D-CRT fields or the use of IMRT seem preferable. 
Keywords: accelerated partial breast irradiation (APBI); conformal radiotherapy; dosimetry; 
electron irradiation; IMRT; Plan Quality Index (PQI); VMAT  
  
Introduction 
Breast cancer is the most common non-skin cancer among women in the developed countries. 
Thanks to breast cancer screening, more and more patients are diagnosed with an early stage 
disease enabling breast conserving treatment involving surgery and radiotherapy [1,2]. 
Accelerated partial breast irradiation (APBI) proved an adequate therapeutic method in certain 
low-risk cases and has been introduced into practice a decade ago [2-5]. Recently, based on 
confirmatory results of the efficacy and safety of most techniques, eligibility for APBI has been 
extended to cases previously considered as medium-risk cases [4-7]. 
The traditional method of APBI has been brachytherapy delivered with interstitial needles, or 
later with innovative balloon-based brachytherapy devices [2,3,6]. Since breast brachytherapy 
needs special infrastructure and expertise, due to the increasing number of patients in the need 
of APBI later, conformal external beam radiation techniques such as 3D-conformal radiation 
therapy (3D-CRT) applying multiple static photon and/or electron fields, intensity-modulated 
radiotherapy (IMRT), tomotherapy, volumetric-modulated arc radiotherapy (VMAT) and 
proton beam therapy were utilized [8-11]. The combination of photon and an ‘en face’ electron 
field aims at improving planning target volume (PTV) coverage and risk organ exposure [10-
14]. IMRT applies complex structure-based planning techniques and variable intensity beam 
fluencies to optimize dose delivery resulting in the reduction of dose inhomogeneity within the 
target volume and of high dose irradiation to normal tissues, producing excellent dosimetric 
results. However, the use of multiple beams could result in a substantial volume of normal 
tissue receiving low or moderate doses. The VMAT technique may further improve the 
previously mentioned indicators by gantry rotation and dynamic multileaf collimation [8,9]. 
Regarding the quality of the radiotherapy (RT) plan, there may be differences among the 
various techniques that differ at the individual patient level. Nevertheless, the comprehensive 
analysis is not trivial. Several indicators describing conformity, homogeneity, target volume 
coverage and organ at risk (OAR) exposure exist [15-17], however, all of these characterize a 
plan only from one point of view. 
The aim of our study was to implement individualized APBI techniques based on both optimal 
dose distribution and risk organ protection. We intended to identify those tumour- and patient-
  
related factors which may help to select the individually most advantageous technique among 
3D-CRT, IMRT, VMAT or photon-electron mixed beam RT. With the aim of comparing 
different RT plans in complex manner, and for selecting the most appropriate plan for an 
individual patient, we adapted an already existing method originally developed for evaluating 
IMRT plans [18] for the special need of evaluating APBI plans. 
Material and methods 
All the procedures followed were in full accordance with the ethical standards of the appropriate 
institutional and national committees on human experimentation and with the 1964 Helsinki 
declaration and its later amendments. The prospective study was registered by the Human 
Investigation Review Board, Regional Human Biomedical Research Ethics Committee, Albert 
Szent-Györgyi Health Centre, University of Szeged, Hungary (registration number: 74/2015-
SZTE). The enrolled patients gave their written informed consent before being registered in the 
study. 
Patient population 
This prospective clinical cohort trial included women after breast conserving surgery, with an 
age of at least 50 years, diagnosed with a unifocal and unicentric breast cancer of any invasive 
histological type or low risk ductal carcinoma in situ (DCIS), with any hormone receptor and 
human epidermal growth factor receptor-2 (HER2) status, pT1-2 (≤30 mm) tumour size 
removed with at least 2 mm free margin, pN0 axillary status diagnosed by sentinel lymph node 
biopsy or axillary block dissection, without extensive intraductal component (EIC), 
lymphovascular invasion or distant metastases. Excision cavity localization at surgery with 
titanium clips was an inclusion criterion. Exclusion criteria included relative and absolute 
contraindications of irradiation. All cases were discussed at a multidisciplinary tumour board. 
Adjuvant systemic therapy was indicated according to the institutional guidelines. Various 
clinical data including tumour bed situation (lateral, medial/central, upper, lower) within the 
breast was prospectively collected. 
 
  
Patient positioning and CT scanning 
The patients were positioned supine on an ‘All in One (AIO) Solution’ (ORFIT, Wijnegem, 
Belgium) breast board with the arms raised over the head. For immobilization, diagonal 
thermoplastic mask fixation (ORFIT, Wijnegem, Belgium) was employed. All patients 
underwent five-millimetre slice-increment planning computed tomography (CT) scanning from 
the sternoclavicular joint to the level of 2 cm below the submammary fold, using a Somatom 
Emotion 6 CT Simulator (Siemens, Erlangen, Germany). 
Target and critical structure delineation 
The clinical target volume (CTV) included the excision cavity (marked with surgical clips) with 
a 1.5 cm margin extended in all directions, limited by 0.4 cm from the skin surface and by the 
outer edge of the chest wall. For compensating daily setup errors and breathing motions, a 
universal planning target volume (PTV)-CTV margin of 0.5 cm was added. As OARs, the 
ipsilateral uninvolved breast, the contralateral breast, the lungs, the heart and the left descending 
coronary artery (LAD) [19,20] were delineated. 
Treatment planning 
In all cases, 3D-CRT, sliding window IMRT and VMAT plans were generated in the Eclipse 
v13.6 planning system (Varian Oncology Systems, Palo Alto, CA, USA) for a Varian 
TrueBeamSTx (Varian Oncology Systems, Palo Alto, CA, USA) linear accelerator with HD120 
multileaf collimator. In 3D-CRT technology, two 6 MV photon fields were used, closing at an 
angle of approximately 120° (Figure 1A). The definition of field directions was based upon 
tumour location and in left-sided cases the situation of the heart and LAD in relation to the 
PTV. For homogeneous dose distribution, further sub-segments were employed, if necessary. 
Sliding window IMRT planning was carried out applying 6 MV photon energy with a five-field 
beam arrangement of 300°, 350°, 40°, 90° and 150° in left-sided cases and 60°, 10°, 320°, 270° 
and 210° in right-sided cases (Figure 1B). If the target volume was located in the medial or 
lateral area of the breast, an additional ±10° rotation was used, depending on laterality. The 
field direction range of dual arc VMAT was defined by the first and last field of the IMRT plan 
(Figure 1C). The isocentre was placed into the geometric centre of the PTV. For comparability 
  
purposes the same optimisation parameters were used during inverse treatment planning 
(IMRT, VMAT). If the shortest distance of the geometric centre of the PTV from the body 
surface (d) was <25 mm, in an additional plan of each technique, an ‘en face’ electron beam of 
4-16 MeV energy was applied (Figure 1D), calculating 2/3 of the whole dose with photon and 
1/3 with electron technique. For these fields Newton’s metal apertures were planned to reduce 
normal tissue exposure. For the PTV, a total dose of 37.5 Gy was prescribed (10 fractions, 3.75 
Gy/fraction, 1 fraction/day, 5 times/week), ≥99% of the PTV receiving 95% of the prescribed 
dose and at least 90% of the PTV receiving 100% of the prescribed dose. Ten per cent at most 
of the PTV was allowed to receive >107% of the prescribed dose. 
 
Figure 1 Beam arrangement in 3-dimensional conformal (A), intensity-modulated (B), 
volumetric-modulated arc (C) radiotherapy techniques and the combination of photon fields 
with an ‘en face’ electron beam (D) 
Treatment plan evaluation 
Conformity and homogeneity indexes of the PTV and dose-volume parameters of the OARs 
were defined in every plan. 
  
Conformation Number (CN) [15]: 
(1) 
PTVref refers to the volume of target receiving a dose equal to or greater than the reference dose, 
in this case the prescribed dose (37.5 Gy). VPTV stands for the volume of target, and Vref is the 
total volume that covered by the reference isodose. 
Homogeneity Index (HI) [16] (D2%, D50%, D98%=dose received by 2%, 50% and 98% of PTV, 
respectively): 
(2) 
To describe plans with a single numerical data, a Plan Quality Index (PQI) was developed based 
on the study of Leung et al. [18], in which the parameters (H)ealthy tissue conformity index, 
(M)erit and (P)enalty functions were generated as follows: 
(3) 
The (H)ealthy tissue conformity index [17]: 
(4) 
The target volume coverage was characterized by the ‘(M)erit function’ parameter [18], to 
verify the performance of hot and cold spots within the PTV. As coverage criteria differ from 
prostate irradiation studied by Leung et al. [18], the following limits were applied to determine 
‘M’. Cold spots were defined by the percentage PTV volume covered with the 100% isodose 
𝐻𝐼 =
𝐷2% − 𝐷98%
𝐷50%
 (Ideal is 0) 
𝐻 =
𝑃𝑇𝑉𝑟𝑒𝑓
𝑉𝑟𝑒𝑓
 (Ideal is 1) 
𝐶𝑁 =
𝑃𝑇𝑉𝑟𝑒𝑓
𝑉𝑃𝑇𝑉
×
𝑃𝑇𝑉𝑟𝑒𝑓
𝑉𝑟𝑒𝑓
    (Ideal is 1) 
𝑃𝑄𝐼 = √(1 − 𝐻)2 + (1 − 𝑀)2 + (1 − 𝑃)2 (Ideal is 0) 
  
curve (at least 90%), hot spots were defined by the percentage PTV volume receiving at least 
107% of the prescribed dose (at most 10%). 
(5) 
The relative volume of the ipsilateral healthy breast (ipsilateral breast – PTV) receiving at least 
25, 50, 75 and 100% of the prescribed dose (BreastV25%, 50%, 75% and 100%, respectively), the mean 
dose to the ipsilateral lung (Lungmean) and the relative volume of it receiving ≥40% of the 
prescribed dose (LungV40%), the mean dose to the heart (Heartmean) and the relative volume of 
it receiving at least 50% of the prescribed dose (HeartV50%), the mean dose to the LAD 
(LADmean) and the relative volume of it receiving ≥20% of the prescribed dose (LADV20%) were 
collected. 
For studying OAR exposure, the calculation algorithm applied by Leung et al. [18] was 
modified to make it suitable for the characterization of risk organ exposure during breast 
irradiation as follows. To describe the exposure of OARs with a single ‘(P)enalty function’ 
parameter [18], specific dose parameters of four OARs compared to the 99% percentile of the 
respective sample population were averaged for each technique. 
In right-sided cases: 
(6) 
In left-sided cases: 
 
(7) 
𝑀 =
𝑉100%
90 + (1 −
𝑉107%
10 )
100
90 + 1
(Ideal is 1) 
𝑃 =
(1 −
𝐵𝑟𝑒𝑎𝑠𝑡𝑉25%
70 ) + (1 −
𝐿𝑢𝑛𝑔𝑚𝑒𝑎𝑛
10 ) + (1 −
𝐻𝑒𝑎𝑟𝑡𝑚𝑒𝑎𝑛
5 ) + (1 −
𝐿𝐴𝐷𝑚𝑒𝑎𝑛
5 )
4
(Ideal is 1) 
𝑃 =
(1 −
𝐵𝑟𝑒𝑎𝑠𝑡𝑉25%
70 ) + (1 −
𝐿𝑢𝑛𝑔𝑚𝑒𝑎𝑛
10 ) + (1 −
𝐻𝑒𝑎𝑟𝑡𝑚𝑒𝑎𝑛
10 ) + (1 −
𝐿𝐴𝐷𝑚𝑒𝑎𝑛
10 )
4
(Ideal is 1) 
  
If the P value were negative in an extreme case (e.g. the exposure of all OARs was high), that 
would have been defined as 0 for further calculations. 
To select the most favourable irradiation plan for a given patient, PQI values were compared. 
In order to determine an arbitrary threshold of PQI difference that indicates a difference in about 
half of the cases, we defined the PQI difference (PQID) as relevant if exceeded the value of 
0.05. Each plan that reached this critical PQID level was referred to a respective ‘winner method 
group’, while that which did not was referred to the group of equality. 
To study if any of the irradiation techniques would be more favourable in subgroups of patients, 
the effects of the volume of the PTV, its distance from the body surface (d) and the quadrant 
where it was situated were analysed. 
Statistical methods 
Continuous variables were expressed as mean ±standard deviation (SD). The means of 
continuous variables in the different ‘winner method groups’ were compared with Welch’s one-
way ANOVA. After significant ANOVA multiple comparisons were conducted with least 
significant difference (LSD) method. The dependence between two categorical variables was 
examined with Pearson’s Chi-squared tests. The relationship between PQI components and PQI 
values was presented with scatter plot. Pearson correlation coefficients were calculated. 
The effect of the addition of an electron beam to photon beams and treatment technique choice 
(3D-CRT vs. IMRT vs. VMAT) was analysed with two-way repeated measures (within 
subjects-within subjects) ANOVA. A p<0.05 was regarded as statistically significant. Statistical 
software IBM SPSS version 24 was used for statistical analysis. 
Results 
Patient population 
The study included 138 cases. Patients belonged to the elderly age group with a median age of 
62.0 (50.1-79.7) years and the majority was postmenopausal (Table 1). In most cases breast 
cancer was diagnosed via breast screening, the mammographic examination showed 
  
circumscribed mass, the tumour was in the outer-upper quadrant of the breast and sentinel 
lymph node biopsy was carried out. Most cancers were invasive ductal carcinoma of grade 1-
2, hormone receptor positive and HER2-negative. The average± SD pathologic tumour size was 
11.3 ± 4.7 mm, the mean ± SD of the surgical margins was 6.8 ± 4.1 mm. The relevant patient 
and tumour characteristics are presented in Table 1. 
Radiotherapy data 
The tumour bed was left-sided in 78 patients (56.5%) and right-sided in 60 patients (43.5%). 
The mean and median PTV volume was 115.6 cm3 and 108.5 (23.7-287.8) cm3, respectively. 
The PTV volume was ≥100 cm3 in 75 patients (54.3%). The distance of the geometric centre of 
the PTV from the body surface (d) was 3.6±1.6 cm (mean±SD) was <25 mm in 29 cases 
(21.0%). 
In most cases, the IMRT and VMAT techniques gave superior plans based on the PQI. 
Parameters reflecting dose distribution within the PTV and conformity are shown in Table 2. 
Based on the data represented in Table 2, in most of the cases IMRT technique is the most 
advantageous regarding homogeneity and avoidance of overdosing, however, conformity is 
mostly improved by VMAT plans. OAR doses according to the technique are summarized in 
Table 3, while OAR exposure according to the side of treatment is shown in Table 3A. OAR 
exposures usually show great variety, however the mean dose to the lung and heart is the lowest 
in 3D-CRT plans. These data shown in detail in Tables 2 and 3 point to the fact that traditional 
plan quality indicators per se are not suitable to choose the optimal technique in an individual 
case. 
The ’H’, ’M’ and ’P’ parameters and the PQI values generated are presented in Table 4. 
Comparing 3D-CRT, IMRT and VMAT plans on the basis of the PQID>0.05 threshold, in the 
whole cohort, the three techniques were equally good in 71 cases (51.4%). VMAT technique 
was optimal in 45 cases (32.6%), IMRT was preferable in 13 patients (9.4%) and 3D-CRT was 
the best in 9 cases (6.5%). 
  
When we analysed the 2 techniques based on inverse treatment planning separately based on 
PQID≥0.05, the PQI was preferable using the VMAT technique in 55 cases (39.9%), while in 
14 cases (10.1%) the IMRT plan was the best. VMAT and IMRT were equally good in 69 
patients (50.0%). 
Comparing the PQI values of patients for whom the 3D-CRT technique was the most 
advantageous to those for whom 3D-CRT was either equivalent with IMRT and VMAT, or 
worse, only the volume of the PTV emerged as significant variable (p=0.017) (Figure 2). The 
mean±SD of the PTV was 159.3±67.9 cm3 in patients for whom the 3D-CRT plan was the 
optimal, 114.4±46.3 cm3 in those for whom the IMRT technique, and 102.9±50.9 cm3 in those 
for whom VMAT was the best; the PTV was 118.3±44.8 cm3 in those patients for whom all the 
techniques gave similar PQI. Post hoc tests indicated that the PTVs were larger if the 3D-CRT 
plan was preferable (3D-CRT vs. IMRT: p= 0.035, 3D-CRT vs. VMAT: p= 0.002, 3D-CRT vs. 
IMRT/VMAT: p= 0.019). 
Comparing the inverse planning techniques (IMRT and VMAT) only, the use of the IMRT 
method gave superior plans in case of superficially located tumour beds (p<0.001) (Figure 3) 
and if the target volumes were located in the medial/central (p<0.032) or upper quadrants 
(p<0.046) of the breast (Table 5). 
In case of superficially located PTVs (d<25 mm, 29 patients) the effect of the addition of an 
electron beam was analysed for all the techniques (3D-CRT, IMRT and VMAT). Two-way 
repeated measures ANOVA revealed that the magnitude of the effect of adding an electron 
beam depends on the chosen technique (significant interaction, p<0.001). Although the addition 
of an electron beam improved the PQI of all treatment plans, its extent was relevant (PQI>0.05) 
only in the 3D-CRT plans, but not in the IMRT or VMAT plans (Table 6, Figure 4). 
  
 
Figure 2 Comparison of Plan Quality Index values of those patients for whom 3D-CRT was 
the most advantageous, 3D-CRT was equivalent with IMRT or VMAT, IMRT and VMAT 
were equivalent but superior to 3D-CRT, IMRT was the most favourable and finally VMAT 
was the most favourable plan, depending on the volume of the Planning Target Volume 
(3D=3-dimensional conformal radiotherapy, IMRT=intensity-modulated radiotherapy, 
VMAT=volumetric-modulated arc radiotherapy) 
 
Figure 3 Plan Quality Index (PQI) was superior with intensity-modulated radiotherapy 
(IMRT) in cases with superficially located target volumes than with volumetric-modulated arc 
radiotherapy (VMAT) 
  
 
Figure 4 The effect of adding an ‘en face’ electron beam to photon beams on intensity-
modulated radiotherapy (IMRT), volumetric-modulated arc radiotherapy (VMAT) and 3-
dimensional conformal radiotherapy (3DCRT) plans as depicted on a profile figure 
In 67 cases with PQI differences >0.05, we analysed which components (H, M and P function) 
were the primary determinants of PQI according to the three RT techniques. We found that the 
best PQI value of a case was primarily dependent on the P function representing OAR exposure. 
This function was the strength of the few (n=9) 3D-CRT-preferred cases with a relatively large 
PTV (mean: 159.3 cm3, range: 81.3-287.8 cm3) as well (Figure 5). 
 
Figure 5 Representation of the effect of the components of the PQI according to the 
preferable plan (IMRT, VMAT or 3D-CRT) 
 
  
Discussion 
In selected early breast cancer cases, APBI is an attractive treatment alternative to whole breast 
irradiation by shortening the course of RT and reducing radiation exposure of healthy tissues 
significantly [1,3,4]. Various teletherapy techniques have been studied for APBI with different 
dosimetric specialities [8,9,21-25]. Our findings indicate that IMRT, VMAT or 3D-CRT may 
be individually superior in at least half of the cases; by selecting the most advantageous APBI 
method, dose homogeneity and OAR exposure could be optimised. The here described PQI that 
takes into account both homogeneity, conformity and dose to various OARs may serve as a 
comprehensive tool for comparing teletherapy APBI plans. 
Many studies analysed the dosimetry of inverse-planning techniques over standard 3D-CRT 
[12,26-30]. The use of IMRT or VMAT improved conformity in all studies, and in most of them 
selected OARs’ exposure as well. With the use of IMRT, the reduction of the dose to the 
ipsilateral breast [26,27], lung and heart [27] was achieved as compared to that of 3D-CRT 
plans. In the study of Rusthoven et al. [27], the ipsilateral breast dose was especially more 
favourable with IMRT than with 3D-CRT in cases with larger PTV/breast ratio and smaller 
breasts. Interestingly, we found altogether 9 cases out of 138 with relatively larger PTVs, in 
which 3D-CRT provided the best PQI probably due to the formula’s complexity. Using the 
VMAT technique, the dose to the lung and heart was lower than that with 3D-CRT [31]. Qiu et 
al. [29] performed a dosimetric analysis of 16 VMAT vs. IMRT vs. 3D-CRT plans. The dose 
(V5Gy, V10Gy) to the ipsilateral breast was significantly lower with VMAT than the other 2 
techniques. Heart exposure was similar among the three techniques while lung dose was 
superior with IMRT and VMAT than with 3D-CRT; IMRT provided the most favourable low-
dose distribution in the ipsilateral lung [29]. 
Stelczer et al. [30] compared the step and shoot and sliding window IMRT methods and the 
VMAT technique to the 3D-CRT technique based on various dosimetric parameters and the 
original PQI approach [18] in 10 low-risk breast cancer cases. While dose homogeneity was 
superior using the sliding window IMRT, in accordance with our results, ipsilateral breast 
exposure was significantly lower with VMAT, and the protection of the lung and heart was the 
best with 3DCRT [30]. V50% of the ipsilateral breast was the lowest in VMAT plans (29.4%), 
  
as compared to 3D-CRT (44.1%) and sliding window IMRT (35.6%) plans. As a consequence, 
they recommend the use of sliding window IMRT for APBI [30]. 
The addition of electrons to photon beams provides more conformal but less homogenous dose 
distribution as compared to the photon only technique. We have found five studies dealing with 
the mixed beam technique in APBI [11-14,32]. All agreed that this approach may lower the 
ipsilateral breast dose; lung and heart doses varied according to study, and obviously the 
situation of the tumour bed [14]. Clearly, the use of electrons should be reserved for tumours 
non-deeply located [10]. In the present study, the addition of a shaped electron field to 3D-CRT 
provided benefit in cases with d<25 mm. We believe that this method could be recommended 
if due to limitations of resources or technology 3D-CRT were utilized for APBI. 
In selected cases, APBI provides similar efficacy and less toxicity versus whole breast 
irradiation with probably better cosmesis and acceptance by the patients [33,34]. Most 
prospective phase II and phase III studies utilizing 3D-CRT technique for APBI have reported 
favourable early and late side effect profile, good or excellent cosmetic results and quality of 
life comparable to that with whole breast irradiation [22,34-37]. Likewise, excellent outcome 
was reported in studies with IMRT [24,25]. Nevertheless, in some APBI studies implementing 
the IMRT [23,38] or 3D-CRT method [39,40] progressive breast fibrosis and poor cosmetic 
outcome was reported. In the most recently reported RAPID trial, more fibrosis and 
progressively deteriorating cosmetic outcome was found after APBI with 3D-CRT/IMRT than 
after whole breast RT [41]. All these studies applied similar doses as the other teletherapy APBI 
trials, but in an accelerated manner (dosing twice daily). Impaired cosmetic results following 
3D-CRT or IMRT APBI could have been also due to the irradiation of larger target volumes 
and more extensive ipsilateral breast tissue as well. The detrimental effect of large irradiated 
volumes on fibrosis-related poor cosmesis had been described in the 1990s [42]. Based on our 
results, if ipsilateral breast dose is a concern we propose the VMAT technique, or if 3D-CRT 
is to be utilised, the addition of electrons. 
Our study suggests that while dose coverage and acceptable homogeneity may be ensured by 
any of the studied techniques, the main differences may be detected in OAR exposure in about 
50% of the cases. Namely the dose to the heart and LAD and the success to limit the radiation 
  
dose to the ipsilateral breast much depend on the selected method. For the evaluation of 
different techniques, different measures have been used in the literature. Most of the studies 
compared various dose-volume parameters, OAR exposure, maximum doses, coverage or more 
complex indexes such as conformity index, conformation number, homogeneity index or the 
PQI which we used [18]. All parameters carry different meanings, but if used singly, 
comparisons are difficult. This is why we aimed at following a comprehensive approach which 
is based on the simultaneous consideration of various factors such as homogeneity, conformity 
and OAR protection. Since in our study conformity and homogeneity did not differ as 
significantly as OAR exposures in the different plans (Figure 5), PQID mainly depended on 
which technique ensured the best comprehensive OAR protection. The strength of our method 
is that we based it on a relatively large and comprehensive data set. 
In conclusion, we find PQI a good tool to evaluate external beam APBI plans. In most cases, 
IMRT and especially VMAT plans give superior PQI values than 3D-CRT plans. 3D-CRT may 
be favourable in cases with large PTV. In superficially situated tumour beds the addition of an 
electron beam results in significant PQI improvement of 3D-CRT plans. Comparing the IMRT 
and VMAT methods, IMRT seems superior in tumours of the superior or inner quadrant of the 
breast. PQI is primarily dependent on OAR exposure. 
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Patient- and tumour-related characteristics 
N=138 
N % 
Menostatus   
Premenopausal (%) 17 12.3 
Postmenopausal (%) 121 87.7 
Mode of detection   
Screening (%) 109 79.0 
Symptomatic (%) 29 21.0 
Mammographic appearance (%)   
Circumscribed mass 71 51.4 
Spiculated mass 57 41.3 
Asymmetric density 7 5.1 
No abnormality 1 0.7 
Microcalcification 
(with or without a parenchymal change) 
12 8.7 
Axillary surgery (%)   
Sentinel lymph node biopsy 121 87.7 
Axillary sampling/block dissection 17 12.3 
Histological type   
Invasive ductal carcinoma not special type 116 84.1 
Invasive lobular carcinoma 2 1.4 
Invasive medullary carcinoma 1 0.7 
Invasive tubular carcinoma 9 6.5 
Invasive mucinous carcinoma 3 2.2 
Invasive papillary carcinoma 2 1.4 
Invasive mixed ductal/lobular carcinoma 3 2.2 
Invasive apocrine carcinoma 1 0.7 
Other 1 0.7 
Nottingham grade (%)   
1 52 37.7 
2 72 52.2 
3 14 10.1 
Estrogen receptor status (%)   
Positive (≥10%) 124 89.9 
Negative (<10%) 14 10.1 
Progesteron receptor status (%)   
Positive (≥10%) 115 83.3 
Negative (<10%) 23 16.7 
HER2 status (%)   
Positive 4 2.9 
Negative 134 97.1 
Adjuvant chemotherapy (%) 8 5.8 
Adjuvant endocrine treatment (%)   
Tamoxifen 10 7.2 
Aromatase inhibitor 30 21.7 
Table 1 Patient- and tumour-related characteristics  
  
 Technique 
V99% V107% CN HI 
(mean±SD, 
%) 
(mean±SD, %) (mean±SD) (mean±SD) 
All cases 
3D-CRT 97.27 ± 1.46 3.51 ± 1.53 0.582 ± 0.063 0.083 ± 0.018 
IMRT 97.16 ± 1.64 0.68 ± 0.73 0.833 ± 0.081 0.045 ± 0.010 
VMAT 97.71 ± 0.87 1.45 ± 1.16 0.901 ± 0.032 0.054 ± 0.010 
PTV< 
100 cm3 
3D-CRT 97.30 ± 1.36 3.46 ± 1.51 0.585 ± 0.061 0.082 ± 0.018 
IMRT 96.85 ± 2.27 0.66 ± 0.79 0.808 ± 0.090 0.046 ± 0.011 
VMAT 97.54 ± 1.16 1.50 ± 1.33 0.900 ± 0.035 0.054 ± 0.011 
PTV≥ 
100 cm3 
3D-CRT 97.26 ± 1.55 3.56 ± 1.55 0.580 ± 0.065 0.085 ± 0.017 
IMRT 97.42 ± 0.72 0.69 ± 0.67 0.853 ± 0.066 0.044 ± 0.010 
VMAT 97.86 ± 0.46 1.40 ± 1.00 0.902 ± 0.030 0.055 ± 0.009 
d< 
2.5 cm 
3D-CRT 97.56 ± 0.75 3.86 ± 1.29 0.589 ± 0.068 0.089 ± 0.016 
3D-CRT+e 95.75 ± 2.35 4.71 ± 1.55 0.765 ± 0.071 0.082 ± 0.014 
IMRT 96.85 ± 3.20 1.07 ± 0.91 0.785 ± 0.081 0.052 ± 0.010 
IMRT+e 95.20 ± 3.42 2.87 ± 1.39 0.828 ± 0.069 0.060 ± 0.008 
VMAT 97.52 ± 1.65 2.35 ± 1.41 0.870 ± 0.037 0.064 ± 0.007 
VMAT+e 96.75 ± 2.19 3.26 ± 1.34 0.886 ± 0.048 0.065 ± 0.008 
Table 2 Partial breast irradiation according to the radiotherapy technique used: parameters 
reflecting dose distribution within the PTV and conformity 
3D-CRT=3-dimensional conformal radiotherapy, CN=conformation number, d=distance of the 
centre of the PTV from the body surface, e=electron beam added, HI=homogeneity index, 
IMRT=intensity-modulated radiotherapy, PTV=planning target volume, SD=standard 
deviation, VMAT=volumetric-modulated arc radiotherapy, Vx%=relative volume of the PTV 
receiving x% of the prescribed dose 
  
  
 Technique 
Ipsilateral breast Ipsilateral lung Heart LAD Contralateral breast Body 
V100% 
(mean±SD, 
%) 
V75% 
(mean±SD, 
%) 
V50% 
(mean±SD, 
%) 
V25% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
V40% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
V50% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
Dmax 
(mean±SD, 
Gy) 
V20% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
V10% 
(mean±SD. 
%) 
V10% rel 
to PTV 
(mean±SD) 
All cases 
3D-CRT 10.1±26.2 15.5±7.3 23.7±8.9 42.4±11.6 3.19±1.40 6.31±3.67 0.93±1.27 0.43±1.19 2.82±3.84 8.90±11.2 13.2±20.5 1.05±1.28 12.8±15.9 17.9±10.7 
IMRT 1.70±1.38 9.06±3.84 18.7±7.6 37.3±11.7 4.81±1.62 7.01±4.18 2.73±1.97 0.66±1.79 3.55±2.11 7.71±5.32 7.5±15.2 1.30±0.52 4.66±7.57 26.4±9.6 
VMAT 0.84±0.72 6.94±3.52 17.2±7.5 35.2±10.4 4.12±1.42 4.87±3.29 2.61±1.78 0.35±1.14 3.65±2.37 6.99±4.72 9.6±18.0 0.79±0.33 0.64±1.73 18.5±5.8 
PTV< 
100 cm3 
3D-CRT 10.5±38.6 12.0±6.1 19.8±8.2 38.1±11.7 3.23±1.43 6.52±3.51 0.95±1.36 0.39±0.96 2.86±3.75 8.11±10.5 13.5±20.6 1.25±1.33 14.4±16.1 21.6±6.5 
IMRT 1.5±1.3 7.0±2.7 14.6±5.8 31.7±10.8 4.43±1.35 6.69±3.10 2.40±1.81 0.66±1.62 3.45±2.25 7.75±5.36 8.1±15.3 1.33±0.55 6.67±8.96 33.7±8.9 
VMAT 0.5±0.4 4.9±2.3 12.8±5.7 30.8±10.2 3.71±1.13 4.41±2.13 2.29±1.64 0.31±0.91 3.48±2.14 6.80±4.54 8.7±15.7 0.80±0.33 0.65±1.15 22.3±6.0 
PTV≥ 
100 cm3 
3D-CRT 9.7±4.8 18.4±7.0 27.0±8.2 46.0±10.3 3.16±1.39 6.13±3.81 0.91±1.19 0.47±1.35 2.80±3.93 9.54±11.7 13.0±20.6 0.89±1.22 11.5±15.9 14.8±12.4 
IMRT 1.9±1.4 10.8±3.8 22.2±7.2 41.9±10.3 5.12±1.76 7.28±4.91 3.01±2.07 0.65±1.94 3.64±2.00 7.68±5.32 7.0±15.3 1.27±0.49 3.00±5.80 20.3±4.6 
VMAT 1.1±0.8 8.6±3.5 20.9±6.9 38.9±9.1 4.47±1.55 5.25±3.99 2.88±1.86 0.39±1.31 3.80±2.55 7.15±4.88 10.4±19.9 0.79±0.32 0.62±2.10 15.3±3.1 
d< 
2.5 cm 
3D-CRT 6.79±4.82 12.8±7.51 17.2±9.08 39.8±12.9 2.60±1.22 6.16±3.70 1.25±1.86 0.46±1.23 2.96±3.70 9.69±12.3 15.4±21.3 1.90±1.61 21.8±18.9 17.9±10.7 
3D-
CRT+e 
2.59±2.28 9.06±5.44 15.1±8.34 27.0±11.8 3.41±1.74 5.96±3.68 1.24±1.33 0.47±1.10 3.44±3.28 11.1±12.5 10.0±16.6 1.28±1.08 18.0±16.3 21.9±6.6 
IMRT 1.76±1.46 7.28±3.43 14.0±6.67 29.9±11.9 4.62±1.81 7.72±4.27 2.97±2.46 0.99±2.27 3.44±2.48 8.94±6.54 10.2±17.9 1.55±0.62 11.6±11.1 26.4±9.6 
IMRT+e 1.17±0.87 6.86±3.83 11.2±5.89 22.8±10.9 4.82±2.12 6.73±4.72 2.40±1.82 0.64±1.35 3.84±3.05 10.7±9.58 17.8±21.3 1.13±0.49 2.38±3.93 24.0±7.8 
VMAT 0.82±0.61 5.42±3.10 12.5±6.81 30.5±11.9 3.85±1.52 5.44±3.27 2.94±2.19 0.62±1.42 4.01±2.61 7.92±5.51 12.7±21.4 1.02±0.42 1.62±3.05 18.5±5.8 
VMAT+e 0.74±0.72 5.63±3.47 10.1±5.68 22.0±10.4 4.31±1.97 5.54±4.26 2.38±1.66 0.49±1.01 4.16±3.05 10.1±9.24 18.7±22.6 0.70±0.28 0.44±1.41 18.8±4.3 
Table 3 Partial breast irradiation according to the radiotherapy technique used: Dose to the organs at risk 
(3D-CRT=3-dimensional conformal radiotherapy, d=distance of the centre of the PTV from the body surface, e=electron beam added, 
IMRT=intensity-modulated radiotherapy, PTV=planning target volume, SD=standard deviation, VMAT=volumetric-modulated arc 
radiotherapy, Vx%=relative volume of the structure receiving x% of the prescribed dose) 
  
  
 Technique 
Heart left-sided cases LAD left-sided cases Heart right-sided cases LAD right-sided cases 
mean 
dose 
(mean±S
D, Gy) 
V50% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
Dmax 
(mean±SD, 
Gy) 
V20% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
V50% 
(mean±SD, 
%) 
mean dose 
(mean±SD, 
Gy) 
Dmax 
(mean±SD, 
Gy) 
V20% 
(mean±SD, 
%) 
All 
cases 
3D-CRT 1.15±1.21 0.77±1.51 4.07±4.33 13.9±12.4 16.6±19.9 0.66±1.29 0.00±0.00 1.25±2.32 2.69±4.32 9.0±20.6 
IMRT 3.45±2.23 1.08±2.16 4.57±2.17 10.5±5.8 13.5±18.3 1.82±1.05 0.12±0.96 2.27±1.10 4.33±0.73 0.00±0.00 
VMAT 3.16±2.01 0.62±1.48 4.90±2.45 9.9±4.6 17.2±21.3 1.91±1.11 0.01±0.07 2.07±0.80 3.46±1.21 0.00±0.00 
PTV< 
100 cm3 
3D-CRT 1.06±1.08 0.68±1.20 3.84±4.20 11.7±12.3 15.0±19.4 0.81±1.68 0.00±0.00 1.54±2.58 3.62±5.07 11.4±22.2 
IMRT 3.01±2.10 0.94±1.70 4.52±2.28 10.6±5.8 14.3±18.0 1.59±0.81 0.28±1.44 2.01±1.17 4.21±0.85 0.00±0.00 
VMAT 2.73±1.90 0.52±1.16 4.58±2.14 9.5±4.3 15.3±18.3 1.70±0.94 0.02±0.11 2.01±0.92 3.37±1.47 0.00±0.00 
PTV≥ 
100 cm3 
3D-CRT 1.22±1.33 0.85±1.75 4.28±4.48 15.9±12.4 17.9±20.5 0.54±0.89 0.00±0.00 1.01±2.11 1.95±3.52 7.0±19.4 
IMRT 3.84±2.28 1.19±2.51 4.61±2.09 10.4±6.0 12.8±18.8 2.01±1.19 0.00±0.00 2.47±1.02 4.43±0.62 0.00±0.00 
VMAT 3.54±2.05 0.71±1.72 5.18±2.70 10.2±4.8 19.0±23.7 2.08±1.22 0.00±0.00 2.12±0.70 3.54±0.97 0.00±0.00 
d< 
2.5 cm 
3D-CRT 1.17±1.43 0.79±1.54 3.48±4.26 13.6±14.9 14.4±19.9 1.36±2.40 0.00±0.00 2.22±2.74 4.82±5.43 16.8±23.9 
3D-CRT+e 1.28±1.09 0.80±1.35 4.80±3.43 17.5±13.5 16.8±18.9 1.20±1.66 0.00±0.01 1.52±1.84 3.25±3.61 0.35±1.23 
IMRT 3.52±2.95 1.68±2.79 4.60±2.52 12.5±6.9 17.4±20.7 2.21±1.29 0.01±0.03 1.80±1.17 4.47±0.92 0.00±0.00 
IMRT+e 2.85±2.12 1.09±1.64 5.67±2.68 16.8±9.0 30.4±19.6 1.77±1.09 0.00±0.01 1.24±0.80 3.03±0.64 0.00±0.00 
VMAT 3.20±2.58 1.02±1.76 5.05±2.88 11.0±5.6 21.6±24.3 2.58±1.50 0.05±0.16 2.54±1.11 4.08±1.72 0.00±0.00 
VMAT+e 2.63±1.91 0.81±1.24 5.86±2.89 15.9±8.6 31.8±21.2 2.02±1.21 0.04±0.10 1.74±0.76 2.78±1.16 0.00±0.00 
Table 3A Partial breast irradiation according to the radiotherapy technique used: Dose to the organs at risk according to the side of 
the radiotherapy 
(3D-CRT=3-dimensional conformal radiotherapy, d=distance of the centre of the PTV from the body surface, Dmax=maximum dose, 
e=electron beam added, IMRT=intensity-modulated radiotherapy, LAD=left anterior descending coronary artery, SD=standard 
deviation, PTV=planning target volume, VMAT=volumetric-modulated arc radiotherapy, Vx%=relative volume of the structure 
receiving x% of the prescribed dose) 
  
 Technique 
H M P PQI 
(mean±SD) (mean±SD) (mean±SD) (mean±SD) 
All 
cases 
3D-CRT 0.598±0.067 0.768±0.069 0.654±0.160 0.595±0.127 
IMRT 0.857±0.087 0.902±0.032 0.544±0.131 0.497±0.126 
VMAT 0.922±0.035 0.868±0.054 0.571±0.128 0.461±0.125 
PTV< 
100 
cm3 
3D-CRT 0.602±0.064 0.771±0.068 0.663±0.177 0.588±0.137 
IMRT 0.836±0.098 0.901±0.035 0.591±0.120 0.464±0.115 
VMAT 0.923±0.039 0.865±0.062 0.613±0.117 0.424±0.113 
PTV≥ 
100 
cm3 
3D-CRT 0.594±0.070 0.765±0.070 0.647±0.145 0.601±0.119 
IMRT 0.876±0.072 0.903±0.030 0.505±0.127 0.524±0.129 
VMAT 0.921±0.033 0.871±0.046 0.535±0.126 0.492±0.128 
d< 
2.5 
cm 
3D-CRT 0.604±0.071 0.753±0.059 0.651±0.223 0.607±0.169 
3D-CRT+e 0.799±0.082 0.704±0.072 0.673±0.155 0.505±0.120 
IMRT 0.811±0.089 0.882±0.040 0.576±0.154 0.495±0.133 
IMRT+e 0.870±0.069 0.789±0.059 0.611±0.134 0.475±0.113 
VMAT 0.893±0.042 0.824±0.065 0.568±0.167 0.490±0.149 
VMAT+e 0.916±0.048 0.778±0.059 0.611±0.136 0.467±0.118 
Table 4 The (H)ealthy tissue conformity, the (M)erit function, the (P)enalty function and the 
Plan Quality Index (PQI) according to technique 
3D-CRT=3-dimensional conformal radiotherapy, d=distance of the centre of the PTV from the 
body surface, e=electron beam added, IMRT=intensity-modulated radiotherapy, 
PTV=planning target volume, SD=standard deviation, VMAT=volumetric-modulated arc 
radiotherapy 
  
  
 
Radiotherapy technique 
[n (%)] 
 
Radiotherapy technique 
[n (%)] 
IMRT 
better 
Equiva-
lent 
VMAT 
better 
IMRT 
better 
Equiva-
lent 
VMAT 
better 
Q
u
a
d
ra
n
t 
Lateral 
4 
(28.6%) 
44 
(63.8%) 
36 
(65.5%) 
Lower 
0 
(0%) 
21 
(30.4%) 
12 
(21.8%) 
Medial/
central 
10 
(71.4%) 
25 
(36.2%) 
19 
(34.5%) 
Upper 
14 
(100%) 
48 
(69.6%) 
43 
(78.2%) 
Table 5 The more advantageous radiotherapy technique in relation to the location of the 
target volume 
IMRT = intensity-modulated radiotherapy, VMAT = volumetric-modulated arc radiotherapy 
 
 
Mean ± SD of 
PQI 
PQID 
95% 
Confidence 
interval for 
PQID 
p 
IMRT 0.495 ± 0.025 
0.020 0.000-0.039 0.055 
IMRT + electron 0.475 ± 0.021 
VMAT 0.490 ± 0.028 
0.023 0.002-0.045 0.037 
VMAT + electron 0.467 ± 0.022 
3D-CRT 0.607 ± 0.031 
0.102 0.070-0.133 <0.001 
3D-CRT + electron 0.505 ± 0.022 
Table 6 Mean differences of PQI values regarding the effect of adding an ‘en face’ electron 
beam to photon beams using IMRT, VMAT and 3D-CRT techniques 
3D-CRT=3-dimensional conformal radiotherapy, IMRT=intensity-modulated radiotherapy, 
PQI=plan quality index, PQID=difference of PQIs, VMAT=volumetric-modulated arc 
radiotherapy 
